We have developed methods for the short-term culture of tumour tissue taken at surgery from patients with cancer of lung, ovary and other sites. The challenge of this work is to determine how to identify in vitro characteristics of the tumour that might be useful for treatment decisions. We used 96-well agarose-coated plates for culture, an incubation time of 7 days and 3H-thymidine incorporation as a measure of proliferation. Culture doubling times, estimated from the reduction in S-phase cells following exposure to paclitaxel, varied upwards from 2.5 days with a median of 4.5 days. We compared dose- Aims: To test the hypothesis that glutathione (GSH) is an important determinant of treatment response for childhood acute leukaemia, blast cell GSH levels were studied in a cohort of children with acute lymphoblastic (ALL) and acute myeloid leukaemia (AML). Background:. GSH is an intracellular thiol implicated in the development of cytotoxic drug resistance and appears to be involved in the control of cell proliferation and apoptosis. In both ALL and AML, the disease at relapse is more resistant to treatment. Several indicators of poor prognosis are well established but the underlying molecular mechanisms leading to resistant disease are still poorly understood. GSH may play a role in mechanisms of treatment failure. Materials and methods: Total GSH was measured by a modified enzyme recycling assay. Cryopreserved blasts from 62 childhood ALL and 13 AML patients were analysed. Results: Median GSH levels in leukaemic blasts were significantly higher in AML (1 1.48 nmol/mg protein) than in ALL ( 6.54 nmol/mg protein, p= 0.0 14).
We have developed methods for the short-term culture of tumour tissue taken at surgery from patients with cancer of lung, ovary and other sites. The challenge of this work is to determine how to identify in vitro characteristics of the tumour that might be useful for treatment decisions. We used 96-well agarose-coated plates for culture, an incubation time of 7 days and 3H-thymidine incorporation as a measure of proliferation. Culture doubling times, estimated from the reduction in S-phase cells following exposure to paclitaxel, varied upwards from 2.5 days with a median of 4.5 days. We compared dose- (Table 1) . Thus, transfer of human chromosome 3 into A2780/cp7O cell lines (cp7O/chr3) significantly increased the sensitivity by approximately five fold (p < 0.05), whereas transfer of human chromosome 2 (which fails to complement mismatch repair in these lines) does not significantly alter cisplatin sensitivity. We propose that cells may be able to bypass lesions in DNA by recombination events during DNA replication and that this is increased upon loss of DNA mismatch repair activity. A prediction of this model would be that the induction of sister chromatid exchanges (SCE's) by cisplatin would be mismatch repair dependant. In order to address this we have examined SCE induction by cisplatin in A2780 models of differing mismatch repair status. SCE's were quantified by Hoechst staining, followed by Geimsa staining of BudR labelled metaphase spreads.This data is summarised inTable 1. Cisplatin induced significantly more SCE's in the A2780/cp7O cell line than the A2780 parental line (p < 0.01). Similarly, the cisplatin induced SCE level in the A2780/cp7O/chr3 transferrants (with restored mismatch repair) was significantly lower than the control A2780/cp7O/chr2 transferrants (p<0.01).
These observations supports the hypothesis that increased recombination bypass during DNA replication is a mechanism of cisplatin drug resistance and that this bypass occurs in a mismatch repair dependant manner. Loss of expression of mismatch repair proteins is associated with resistance to mono-functional and bifunctional alkylating agents. An association has been shown between loss of MLHl and resistance to the clinically important chemotherapy agent doxorubicin (Drummond et al. J Biol Chem, 1996, 271,19645-8) . In order to define this association further we have examined the effect of loss of MLH I in S. Cerevisiae and in human ovarian cell lines.
Sensitivity of wild type S. Cerevisiae to doxorubicin was compared to an isogenic strain deleted for the scMlhl gene. Clonogenic assay demonstrated an IC50 of SlM for the wild type strain compared with 651iM for the scMlhl deleted strain. This represents a relative resistance of 13 fold (p<0.05).
The cell line A2780/cp7O is a cisplatin resistant derivative of A2780 Loss of DNA mismatch repair (MMR) has been described in a number of tumour types and leads to microsatellite instability This is observed in certain cases of colorectal adenocarcinoma and may have clinical relevance due to mismatch repair defects altering chemosensitivity towards certain classes of antitumour agent. This study has examined microsatellite instability, mutant frequency, and chemosensitivity of two murine adenocarcinoma tumour models, the MAC15A and MAC13 lines DNA was extracted from fresh and paraffin embedded normal and tumour tissues up to twenty years old. A preliminary study of two microsatellite regions (DI 9M1T36 and D7M1T62) demonstrated that both adenocarcinoma lines exhibit Imicrosatellite instability, with an increase in the number of microsatellite alleles over time compared to normal tissues. The observed instability was associated with a HPRT mutant frequency (MF) of 39 1x10-6 (±5.943 xl0-6) for the MAC15A, which is significantly higher (p<0.005) than the <1 74 x10-6 (+0.03 x10-6) for the MAC13 adenocarcinoma. This compared to a MF of l52x10-6 (±1.68 x10-6) and2 22xl106 (±1 077x10-6) for the MMR deficient HCT1 16 and MMR normal SW620 human adenocarcinoma cell lines respectively. Defects in misIltatch repair have been found to result in a particular pattern of chemosensitivity towards agents such as 6-thioguanine (6-TG) and cisplatin The IC50 for cisplatin was 1.003pM (±0 857) for the MAC15A and 0.785M (+0.474) for the MACI3 For 6-TG. the IC50 values were significantly different (p<0 005) at 0.623PM (+0.1347) and 0 0387gNM (+0 0189) for MACI5A and MAC 13 respectively.
This work therefore demonstrates two mnouse adenocarcinoma tumour models showing evidence of microsatellite instability associated with significantly differing mutant frequencies and chemosensitivity towards 6-TG but not cisplatin. 3) and HCTI 16+3M2 (addition of a normal copy of chromosome 3. with subsequent loss of expression of hMLHI). Expression of hMLHl was confirmed by western blot and a microculture tetrazohium assav used to measure cell growth. Loss of hMLHl protein expression conferred an increase in resistance to -Fluorouracil plus Leucovorin ( 1.8 fold) . but an increase in sensitivity to Oxaliplatin (4.3 fold). Mitomwin C (3.3 fold) and SN38. the active metabolite of Irinotecan (2.8 fold) . Therefore it was clearlv demonstrated that hMLHl does have a function in predicting response to these chemotherapeutic agents in an in vitro setting As loss of hMLHl expression was observed to confer altered sensitivity to agents which induce a range of insults to DNA a wide role for this protein in the recognition and signahng of cell damage uas suested. IV-C at 254nm. After 2-3 days incubion, sensIifvities of each sbain were measued by colony surving tadcon. Compared to wid-ype (wt) CODP sensivty IC-=1.0wnM), knoig out scPMSl had no effect (IC-=1.1mM, P>0.05), but lie so"rE muntat showed a sifcaIt 2-3-old increase in COOP resistance (lC-=1.5mM, P<0.05) . No to detr n colony sm-viving fion. Iblefus mut asa signfi restas to cisplatin (C90 = 1.1mM) ran with the wild type strai (lC90 = 1mM, p0.05 The n/i mutt was 1.5 fod mereim thith wild type ntai (1C90 = 1.5mM, p<005) The n2 mutant was the mst resistantmaI being 2 fold me resistant to cisplatin than the wild type In (1C90 = 2mM p<0.05 Disuption of the sddUf) gum caused a 10-fold iease in the son s fard mntn rate to L-aavani rsstauc (wid type forward mutatin rate = 3 x 0 s/cdl nl mutat forwad mutatio rae = 3.1 x 1'5 events/cell) Dinuption of the xP)I8gnm cisd a 29-fold increase in thes forward mutatio rate Oxus] imitat forward mutatio rate = 8.7 x 0io events/cel) The farward mutation rate for the xdl2 mut strain was no gmater than th observed for the wild type sain (9.7 x le events/el) Thus km of mWU2 confers iimsd csmpla resine t does not cause the acqution of a phanype. Conversey the pusl mutant had a m t plntype bt did not have inceaed cisplatin resistance erapard to the wid type stan. Tle li mutn had both incread cispatin resistance and a m phntpe.
The scMB2 genm was orgialy ixtified by vitue of its sequmce hamokgy to other yeast MVTL gees. In order to identifir possible humn h n of the scL2 gmne we have utilisud PCR with ruImdant uimrs against two region of conserved amio acid supse within the MUTL gum faily. The 3' pimer n rengmies the MLOHI box which encodes for the acid sequaw GFRGEAL and is completly consved aming the MutL proteins. The 5' pimer anneals to a rego awoding for a slight less co.ueved amio acid sequene than the 3' Pima. Rdunant PCR product was amplified from normal human cDNA revers transcibed fiom icating, normal foresin keratnocyte RNA. The WERI-Rbl and archival material indicates that the expressed p53 is wild type Our in vitro study using the Y79 cell line indicates that the balance of cell proliferation and cell death is influenced markedly by FCS concentration and to a lesser extent oxygen availability and that optimum p53 induction is observed under growth factor and oxygen limiting conditions We conclude that rennoblastoma cells are protected from p53 mediated programmed cell death by the production of survival factors which are stimulated by the diffusion of oxygen and growth factors delivered to the tumour bv the blood vessel and that p21 is involved not in cell death but in cell survival. Recent Mutation of the tumour suppressor protein p53 has been implicated in resistance of ovarian cancer to cisplatn We have determined the p53 and bcl-2 status of a pair of human ovarian tumour xenografts (PXN65 and PXN100) curable with cisplatin.
and investigated the effects of a single dose of cisplatin on induction of genes downstream to p53 and on DNA repair. Both of these tumours fail to grow in vitro. Functional p53 status was determined by measuring MDM-2 and p21 'PI' mRNA induction 4 hours following 5 Gy by northern blotting. Single-strand conformational polymorphism and sequencing of exons 5. 6. 7 and 8 of P53 were carried out using standard techniques. Bcl-2 protein levels were determined by immunoblotting. Following a single dose of 6mg kg-' cisplatin i.p. induction of p21%'-Fc. MDM-2 and BAX mRNA was determined by northern blotting and gene-specific repair was determined by quantitative PCR of a 1.9Kb fiagment of H-RAS. The PXN65 tumour showed no re-growth after 350 days following 3 X 6mg kg-' i.p. cisplatin The PXN100 tumour showed no re-growth after 300 days following 4 X 8mg kg-' i.p. cisplatin-Following a single dose of 6mg kg-' cisplatin the growth delay was 76.1 and 24.9 days for PXN65 and PXN100. respectively. p21Fl l and MDM-2 mRNA levels were elevated 4 and 2.5 fold respectivelx followne irradiation in PXN100, suggesting wild type p53 fumction. p21'A'F and MDM-2 mRNA were barel detectable following irradiation in PXN65.
suggesting no wild type p53 function. No mutations were found in PXN100. but a deletion of bp 868 at codon 290 and a insertion of GTGGTGAG was seen in PXN65 causing a frame shift and premature stop at codon 306. High levels of bcl-2 protein were present in both xenografts and levels were elevated following irradiation. p21wF~cP'. MDM-2 and BAX mRNA levels were induced 3-fold at 24 hours following a single dose of 6mg kg-' cisplatin in PXN100. but were undetectable in PXN65. There was measurable damage to the H-RAS gene following a single dose of 6mg kg-cisplatin that was repaired by 24 hours post treatment in both tumours. This work suggests that p53 may not be the primary determinant of response to cisplatin in these human ovarian cancer tumour xenografts.
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DOES We investigated the expression of p53 tumour suppressor gene protein and its related products mdm2, wafl and bcl-2 proteins in human germ cell testicular tumours (GCTTs) using Western blot or/and immunohistochemical analyses. Except differentiated teratoma, all GCT tumours of untreated patients (77) were immunoreactive for p53 to various extent. Seminomas and embryonal carcinoma components had the most positive immunostaining. P53 showed a significant inverse correlation with stage of disease (P< 0.003). Numerous recent studies strongly suggest that the p53 in GCT cancer has wild-type character. In contrast with mutant p53 the wild-type p53 is able to induce cyclin dependent kinase inhibitor i.e. wafl protein (El Deiry et al., Cell 75:817, 1993) , which is a crucial protein in cell-cycle control. Therefore, we analysed GCTT samples (36) for wafl using Western blot technique. There was no sign of wafl expression in any tumours investigated. The same cohort studied for wafl was analysed for mdm2 by Western blot and immunohistochemistry as well. 30% of GCT tumours displayed mdm2 expression. The failure of wafl expression in GCTTs can not be explained by p53 inactivation caused by mdm2, since 70% of tumour samples did not express mdm2 protein at all. We also screened bcl-2 expression in patients with GCTTs using immunohistochemistry. 58% of tumours stained with anti-bcl-2. The bcl-2 expression was clearly dominant in tumours of advanced stages and the incidence of bcl-2 exprression was higher in tumours from metastatic patients than in tumours from metastatic-free patients (P < 0.000). Our findings suggest that bcl-2, during suppression of wafl may interfere with the functional properties of p53 protein and this interaction may be a mechanism by which bcl-2 exercises its oncogenic potential. Neuroblastoma is a chemosensitive tumour and combined chemotherapy is considered an important treatment modality. Like many early onset tumours. neuroblastomas do not have p53 mutations; this play a role in drug sensitivity. However, i t has been suggested that p53 may be inactivated in neuroblastomas because of cytoplasmic sequestration. We have investigated if the p53 response pathway differs between drug sensitive and resistant neuroblastoma cell lines. The cell line model systems used were: SH-SY5Y, a neuroblastic clone (N-type), and SH-EPl, a substrate adherent clone (S-type). Both are subclones of SK-N-SH which has wtp53. Etoposide produces equal levels of DNA damage in both cell types but clonogenic assays demonstrate that SH-SYSY are >3 fold more sensitive than SH-EPl. Before etoposide treatment p53 is located in the cytoplasm of both cell types, although at significantly higher levels in SH-EP1. Four hours after drug treatment the majority of p53 translocates to the nucleus in SH-SYSY and cells undergo apoptosis whilst in SH-EPI the majority of p53 remains in the cytoplasm However, in SH-EPI etoposide results in a 12.9-fold increase in p21"'"' RNAand protein and cells arrest in G1 -phase of the cell cycle whereas in SH-SYSY p21 increases by only 3.4-fold and cells undergo apoptosis in less than four hours. In SH-EPl cells 7 days after etoposide treatment (1 h) the cells have a morphologically distinct neuronal phenotype. These daia suggest that neuroblastoma types that retain the p21 upregulation pathway may be relatively resistant to drug induced apoptosis and differentiate rather than die in response to etoposide. p21 has previously been demonstrated to be essential for survival of differentiating neuroblastoma cells in response to retinoic acid. Analysis of the expression of the Bcl-2 family members can not explain the differential sensitivity. Levels of expression of Bax, Bak and Bcl-XL are similar in the SH-EPI and SH-SY5Y cells, whilst paradoxically Bc1-2 is overexpressed in SH-SY5Y, the apoptosis sensitive cell type. In conclusion, firstly we find that in neuroblastomas where the majority of wtp53 translocates to the nucleus cells rapidly undergo apoptosis. Secondly in cells which induce high levels of p21 cell cycle checkpoints are activated and cells undergo further differentiation and survival. We have examined the expression of the anti-apoptotic bcl-2 family protein, bcl-w, in more than 50 colorectal adenocarcinomas, using immunohistochemical techniques. We have found that >90% of tumours show expression of the protein, which was cytoplasmic in location. No expression of bcl-w was observed in adjacent normal epithelium taken from the same patients. No correlation was found between expression of bcl-w and bcl-2 and p53 expression and Duke's stage. In only 2 out of 9 adenocarcinomas of the stomach was sporadic bcl-w immunoreactivity observed. Adenocarcinomas from other epithelial tissues (breast, cervix) failed to demonstrate any expression of bcl-w. We are currently investigating the expression of bcl-w in adenomatous polyps. In the adenomas that have been examined so far, only 1/9 showed bcl-w expression although 6/9 demonstrated various levels of bcl-2 expression. We are currently seeking to expand this study to assess the importance of bcl-w in colorectal cancer. Cellular responses to novel (NU/ICRF 505) and established (camptothecin, CPT) topo I inhibitors have been investigated in a panel of human cell lines and drug sensitivity was associated with the presence of functional p53 protein (with or without p21WAFl/CIPl induction and G i/S block). In order to gain insights into less sensitive p53-independent processes, basal expression and temporal induction of 4 key members of the Bcl-2 family were determined in wild type p53 chemosensitive A2780 ovarian cancer cells and mutant p53 chemoresistant HT29 colon cancer cells. Cells were exposed to drugs at their IC5o concentrations and proteins measured by Western blot analysis for up to 72 hr. Bcl-2 was not detectable in both cell lines nor was it induced after drug exposure. Likewise Bcl-xs was not detectable prior to drug treatment nor stimulated post drug treatment. High basal levels of the apoptosis inhibitor protein BCI-XL were measured in HT29 compared to A2780 whereas the reverse situation was recorded with the death inducing protein Bax. There was no evidence of Bcl-XL induction in both cell lines. CPT produced a 4-fold maximal increase in HT29 cells and 2-fold maximal increase in A2780 cells in Bax protein at 36 hr post-treatment. However, NU/ICRF 505 had no significant effect on Bax protein levels. Thus, in vitro drug resistance to topo I inhibitors is also associated with a high Bcl-xl/Bax ratio as well as the presence of mutant p53. In addition, these data provide evidence that cells can respond to the DNA damage induced by different topo I inhibitors through the selective induction of apoptosis modulating proteins.
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Transfection of bax into resistant human ovarian carcinoma cell lines confers no sensitisation to chemotherapeutic agents. P.Beale, P. Rogers, S. Hobbs, F. Boxall, L. Kelland. CRC Centre for Cancer Therapeutics, Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK The BCL-2 family of proteins are known to be important in the process of apoptosis. The mechanism of action of BCL-2, an anti-apoptotic protein is unknown but it may act via ion channel pumps in the mitochondria. BAX can form heterodimers with BCL-2 and antagonise this function leading to a pro-apoptotic effect. Some studies have shown that overexpression of BAX can lead to sensitivity to some chemotherapeutic agents but not to others. We investigated two human ovarian carcinoma cell lines which are resistant to cisplatin (SKOV3, with intrinsic resistance and A2780cisR, with acquired resistance). Cell lines were transfected with bax coupled to an HA tag cloned into the bicistronic plasmid vector pIRES-P (EMBL:Z75185) or with an empty vector. Clones were selected using puromycin. BAX overexpression was confirmed by western blotting (1.4 fold increase for A2780cisR and 5.8 fold for SKOV3). Cell sensitivity to 8 drugs was assessed by 96 hour sulforhodamine B cytotoxicity assay (tables 1, 2) . There was marginal sensitisation to cisplatin in the A2780cisR compared with the puromycin control (RF 1.3) . For all other drugs tested there was no significant sensitisation. (17-(3-pyridyl) androsta-5,16-dien-30-ol), when tested as its 0-acetate prodrug in vivo in mice, reduced circulating androgens and caused regression of androgen dependent organs. Studies with the enzyme from murine and human testes showed that abiraterone is a slow binding "irreversible" inhibitor. The extent of inhibition increased with time and appeared enhanced by preincubation with the enzyme. The apparent first order rate constant for the inhibition of the human enzyme was dependent on the concentration of abiraterone, being 0.14 ± 0.03 min-' with 5nM and 1.2 ± 0.3 min' with 20nM abiraterone (in the presence of 1pM pregnenolone), and was inversely dependent on the pregnenolone concentration in the assay, being 1 The monoterpene, limonene, is found as its R-enantiomer in orange peel and other plant oils. R-Limonene causes regression of both spontaneous and chemically induced tumours in rats and is in clinical trials in advanced cancer patients. RLimonene undergoes extensive metabolism in vivo and in human plasma, R-perillic acid and its non-chiral reduction product, dihydroperillic acid are among the most abundant metabolites, whilst the glucuronide conjugates of R-perillic acid and Rperillyl alcohol are found in urine. Quantification and characterisation of the metabolites of limonene is important, because the known Phase metabolites are more potent inhibitors of small G protein isoprenylation than limonene. Using HPLCatmospheric pressure chemical ionization mass spectrometry (LC/APCI/MS), a novel metabolite has been detected in both human plasma and urine, which appeared to be an isomer of perillic acid (Poon et al., 1996 Drug Metabolism and Disposition 24: 565) .
The structure has now been confirmed by chemical synthesis. 4-Acetyl-1-methylcyclohexene was converted into its triflate by base catalysed reaction with triflic anhydride in the presence of the hindered base, 2,6-di-tert-butyl-4-methyl pyridine. The triflate was methoxycarbonylated to give p-menth-1,8-dien-10-oic acid, which by LC/APCI/MS, was identical with the novel metabolite detected in human plasma.
Previous reports on the activity of perillic acid against isoprenylation enzymes refer to the S-enantiomer, although it is the R form which is produced from R-limonene. In this study, we also describe the synthesis of R-perillic acid via a two-step oxidation from the corresponding R-perillyl alcohol. The above monoterpenes were tested for inhibitory activity towards famesyltransferase (FTase) Cell cycle effects after 3 hrs MMC exposure (1.5 pM) have been assessed using FACS analysis of fixed propidium iodide-stained cells.All three cell lines exhibit G2 block 24 hrs post MMC exposure but vary in their subsequent response. H647 cells are attempting to divide by Day 3 , and then rapidly die. Some H460 cells persist in G2 block for at least 7 days before dying, but a considerable number of A549 cells remain in apparently irreversible G2 block, or as large cells, for at least 21 days after drug exposure (NB. Control cells maintained for this period were seen to be cycling normally).
In an attempt to gain further information with regards to the death of these cells after exposure to MMC a number of methods were employed. Estimation of total cell number over 21 days shows H647 and H460 cell numbers to fall far more rapidly than A549 cells as would be expected. Exclusion of propidium iodide combined with Rhodamine 123 uptake by the cells (analysed by FACS) allows a simultaneous measure of cell viability and of mitochondrial membrane potential (alterations associated with onset of apoptosis). Marked differences were apparent between the 3 ceil lines with respect to changes in mitochodrial function, and the percentage of necrotic cells present at each timepoint, but there was no evidence of apoptosis using this technique (We are currently attempting to confirm these results using an assay of Annexin V-binding. Results will be presented).
In conclusion, the 3 NSCLC cell lines react very differently to short term MMC exposure but it would appear that their overall long term survival is the same at this drug concentration, and that the colony forming assay reflects this more accurately than the MTT assay. These results suggest that the MUT assay is not a suitable measure of cellular sensitivity for drugs, such as MMC, which cause cell cycle arrest over prolonged periods Cancer, 26, p638, 1997 ). However, in another report, decreased telomerase activity was associated with non-specific tumour cell killing 'in vitro' ( Faranoi et al, Clin. Cancer Res, 3, p579, 1997 (Lavie et al. (1996) JfBiol.Cshem. 271: 19530-19536 The pluripotent cytokine, TNFa, is known to cause apoptosis in tumour cells containing its cognate p55 receptor. However, the extent of apoptosis in these target cells is attenuated by the activation and nuclear translocation of the transcription factor NFicB, processes that are also initiated by the binding of TNFa to p55. The key steps in the activation and translocation of NFKB are the phosphorylation and subsequent proteasome-mediated proteolysis of a protein called IKBa, which binds to and sequesters this transcription factor in the cytoplasm. The inhibition of the proteasome-mediated proteolysis of IKcBa would therefore result in the blockade of NFKB nuclear translocation and, presumably, the NFKB-induced expression of the protective genes which limit the extent of apoptosis (1, 2) . We have developed a series of peptidyl a-keto aldehyde inhibitors of the chymotryptic activity of proteasome, one of which Bzl-Leu-Leu-Leu-COCHO (I), inhibits the enzyme with a K, of -3.0 nM (3).
We now wish to report that this inhibitor greatly accenuates the TNFa-induced apoptosis in HeLa cells, when used at concentrations of 10 ,uM (see Table) . The induction of apoptosis is the mechanism through which a variety of cytotoxic drugs kill tumour cells. The precise sub-cellular pathway through which any of these drug initiates apoptosis is as yet unclear. In the present communication we demonstrate that the use of selective protein kinase inhibitors sensitises HL-60 tumour cells to the induction of apoptosis. In this respect Wortmannin and LY294002, both inhibitors of P13 kinase, enhance the induction of apoptosis in these tumour cells by up to two fold. These data indicate that PI3 kinase is essential for cell survival and when inhibited an enhancement of the rate of apoptosis induced in this case by actinomycin D, Camptothecin, etoposide and cycloheximide is seen. This is in line with some recently published work indicating a role for P13 kinase as an anti-apoptotic survival factor. Our data also indicates that PI3 kinase does not mediate its survival effects through the p7OS6 kinase pathway. Protein kinase C (PKC) like PI3 kinase has also been suggested to play a key role in the regulation of apoptosis. Using a series of PKC inhibitors including PMA, staurosporine and calphostin C we were able to demonstrate that inhibition of PKC by calphostin C, but not the other two agents, increased the sensitivity of HL-60 cells by 2-3 three fold to the induction of apoptosis by a number of cytotoxic agents. Experimental data suggests that calphostin C may act by its selective inhibition of PKC zeta. Retinoblastoma (Rb), derived from retinal neuroepithelial cells, is the most common intraocular malignancy of childhood, and has traditionally been treated by enucleation or radiation of the affected eye. Recently, chemotherapy/cyclosporine A combined with laser or cryotherapy has been used as an alternative therapy for Rb. In this study, we assessed the effects of vincristine (VN) and cisplatin (CP) on cell death in human Rb cell lines (Y79 and WERI-Rbl), and investigated the potential of sodium butyrate (SB), which can induce dose-dependent apoptosis or differentiation in Rb (1), to augment chemotherapy-induced apoptosis.
The dose-response of Rb cell lines to VN and CP was established (LD50 . Cultures treated with lOiiM VN or CP were assessed using cell morphology, DNA stains and DNA electrophoresis. The effects of cycloheximide (CHM) and actinomycin D (AD), and endonuclease inhibitors zinc sulphate (Zn) and aurintricarboxylic acid (ATA) were also assessed. Rb cells were also exposed to combined chemotherapy/SB<2mM and examined as above. Bleomycin (BLM) is a water-soluble glycopeptide used in combination chemotherapy against germ cell tumours such as testicular teratoma and ovarian cancer, resulting in a 90% response rate in the case of the former. However treatment with BLM is hampered by a serious pulmonary fibrosis occurring in between 5% and 10% of patients with a 2% mortality rate (Levi et al (1993) J Clin Oncol 11 1300). This can lead to the death of potentially curable patients and is related to cumulative dose, renal impairment, adjunctive classic radiotherapy, the use of supplemental oxygen or the patient being aged over 70 (Comis (1992) The human pim-1 proto-oncogene was first cloned from the B-cell leukaemia 380 cell line and from a human genomic library (Nagarajan et. al., 1986 , Proc. Natl. Acad. Sci. USA, Vol 83, p. 2556). The mRNA of the pimproto-oncogene is 2.9Kb length. A full length pim-1 cDNA was cloned from the human chronic mylogenous leukaemia cell line K562. The pim-1 cDNA Open Reading Frame is 939 nucleotides and encodes for a 313 amino acid protein (Domen et. al., 1987, Oncogene Research, Vol 1, p. 103) .
We investigated human pim-1 proto-oncogene expression in four NonHodgkin's lymphoma cell lines; Daudi, MCI 16, Namalwa and Raji. Our data indicate that pim-1 is overexpressed in all of these cell lines. We also cloned the full length pim-I cDNA from the Raji cell line.
We have investigated the role of pim-1 in regulating entry into apoptosis in these cell lines by transfecting them with pim-sense and antisense constructs. Our data suggest that the down regulation of pim-I expression in these cell line results in a high rate of apoptosis whereas pim-1 overexertion leads a small but detectable increase in apoptosis compared to control cells.
BLM polymeric vesicles were prepared from palmitoyl glycol chitosan (GCP41) and cholesterol by remote loading in response to an ammonium sulphate gradient (Haran et al (1993) Biochem Biophys Acta 1151 201). Briefly, GCP41 ammonium sulphate vesicles were incubated with BLM and BLM was found to traverse the membrane and accumulate within these vesicles. These GCP41 based BLM vesicles were 600nm in size and had an encapsulation efficiency of 0.5U BLM:lmg GCP41. BLM polymeric vesicles were stable at room temperature for 28 days. The GCP41 based BLM vesicles also demonstrated good plasma stability, with 70% BLM remaining encapsulated over 24 hours. This is the first report of a large molecular weight drug being loaded into polymeric vesicles by a remote loading method. GCP41 based BLM vesicles are to undergo in vivo testing. The product of the Retinoblastoma (Rb) gene has a critical role not only in tumor suppression but also in the regulation of cell growth and differentiation. In contrast to the loss of pRb reported in several non G.I. malignancies, pRb is overexpressed in colorectal cancer (CRC). In order to address what might induce a recessive cancer gene to become overexpressed in CRC we analysed a transcription factor E2F-I that binds to unphosphorylated pRb in the GI phase of cell cycle control. Western Blotting was carried out on a group of 32 CRC surgical specimens (each with its normal control), and 2 CRC cell lines, (SW480, SW620). Monoclonal antibodies (Pharmingen) were used for all '3 proteins: pRb, unphosphorylated pRb, E2F-1. We have found 21/32 (65%) tumors have increased pRb expression; 19/32 (59%) tumors have increased unphosphorylated pRb expression; and 31/32 (97%) tumors have increased E2F-I expression. Within the cell lines the results mirrored the events in CRC. Using the E2F-1 antibody an additional band was observed at II Okd, which may represent a pRb-E2F-I associated complex and this was also found to be increased in tumors compared to the normals by 22/32 (69%).
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In conclusion, failure of increased pRb in CRC to inhibit proliferation may be related to an overall increase in the E2F-1 transcription factor. The aim of this study was to investigate the cellular events mediated by p53 following exposure of cells in vivo to ionising radiation. In adult mouse skin, distinct populations of keratinocytes respond to p53 stabilisation by entering an apoptotic pathway or executing a cell cycle block.
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Apoptosis, as determined both by in situ tunnel assay and by morphology is restricted to the matrix region of the hair follicle and can be detected 4hrs after exposure to 4Gy ionising radiation. BrdU labelling studies demonstrate that matrix cells are capable of entering the apoptotic pathway from G2/M, as well as G 1.
Interfollicular and non matrix follicular cells respond to radiation by initiating a cell cycle block, as measured by BrDu incorporation, which is detectable 24hrs after exposure to 4Gy. Pre treatment of skin with the tumour promoter TPA, which induces an increase in cellular proliferation rate, results in a cell cycle block within 4hrs of radiation exposure in the same cell population. Similarly, highly proliferative two week old mouse skin shows a cell cycle block 4hrs after exposure to radiation. Both cell cycle arrest and apoptosis following radiation. are p53 dependent, as they are not detected in p53 knockout mice after radiation exposure.
These results suggest that cell cycle arrest and apoptosis following exposure of mouse epidermis to ionising radiation is cell type specific. The timing of cell blockage after damage is dependant on the proliferative state of the cell. However, ability to enter the apoptotic pathway is independent of cellular proliferation rate and seems likely to be dependent on the differentiation status of the cell. Radiation induced genomic instability may be an important contributor to carcinogenesis. The aim of this work was to investigate the initial and delayed frequency of micronucleated cells and apoptosis after irradiation. X-ray and a-particle irradiation were carried out in AGO1522B primary human fibroblasts.
Cells were allowed to grow under normal proliferative conditions, without the use of cytochalasin B. Micronuclei were scored using daughter cell analysis on acridine orange stained cells. Apoptosis was assessed by morphological criteria on acridine orange stained samples, by DNA fragmentation with in situ 3-OH DNA end-labelling and by detection of phosphatidylserine expression on the outer surface of the cell membrane with Annexin V.
We have shown in our experiments that there are significant differences between X-ray and a-particle irradiated fibroblasts in both the yields and time-course of micronuclei production. An initial peak in micronuclei and apoptosis yield is found 3 days after both, X-ray and a-particle irradiation. In the case of 3 Gy of a-particles a delayed peak on day 8 was observed. Both types of irradiation also induced delayed genomic instability at later times (8-30 days). aparticle irradiation is more efficient in producing genomic instability and, in the case of higher doses, the peak in micronuclei formation and apoptosis is at later times. The existence of genomic instability was also confirmed by cell survival assays on day 0, 8, 14 and 24 after irradiation. In comparison with short term samples, damaged cells scored at later times are more frequently found to be heavily micronucleated. Also, at later times, apoptosis became a greater contributor to total cellular damage than micronuclei production.
We find that micronuclei and apoptosis frequency curves, at early and delayed times have a similar time dependency. Morphologically, it is difficult to distinguish between apoptosis and heavily micronucleated cells. An in situ 3-OH DNA end-labelling technique was employed to confirm detection of apoptotic cells. It confirmed the time dependence of apoptosis induction but values were higher than with conventional morphological analysis. A possible reason is that in situ 3-OH DNA end-labelling is able to detect three different morphological stages of apoptosis, whereas conventional staining detects only the last stage, fragmentation of the nucleus.
Annexin V detection of phosphatidylserine externalisation, was used as a marker for the early stages of apoptosis after a-particle and X-rays irradiation. We find that a-particles are more efficient in apoptosis production then X-rays. Also there are differences in the time course. The peak of apoptosis production is 1 day after a-particle irradiation with a decrease up to day 6. The fraction of apoptotic cells remained dose dependent for all time points. For X-rays the fraction of apoptotic cells starts to increase on day 2 and slowly decreases afterwards, independently to dose. These experiments confirm that phosphatidylserine expression is an early event in these irradiated fibroblasts. In control flow cytometry experiments we found that only a small fraction of fibroblasts detach from the substrate and undergo apoptosis.
We demonstrate in this work an evidence of radiation-induced genomic instability in normal human fibroblasts which have being cultivated under normal proliferative conditions. The results suggest a considerable contribution of programmed cell death to total cellular damage, especially at delayed times after irradiation. The principal types of skin cancer, i.e., basal cell carcinomas (BCC), squamous cell carcinoma (SCC), and malignant melanoma vary widely in their metastatic potential. Thus, while SCCs, and especially BCCs rarely metastasise, malignant melanoma frequently give rise to metastases. The aim ot this work was to investigate the possibility that the wide difference in the metastatic propensity of these different types of skin cancer was due to different levels of matrix metalloproteinases (MMPs), a group of endopeptidases causally involved in cancer spread.
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MMP-1 and 3 levels were measured by ELISA (prototype kits from R & D Systems) while MMP-2 and 9 activities were determined using gelatin zymography.
Levels of MMP-1, 2, 3 and 9 in BCCs and SCCs were not significantly different. However, for MMP-1, 3 and 9 (both precursor and active forms), levels were significantly higher in both BCCs and SCCs compared with the melanomas. For MMP-2, precursor levels were higher in SCCs compared with melanomas, while for active MMP-2, activities were higher in BCCs than in melanomas. Within the combined group of skin tumours, a number of correlations between the different MMPs were found. Thus, MMP-1 levels correlated significantly with both the active (r = 0.58, p = 0.0001, n = 44) and precursor forms of MMP-2 (r = 0.37, p < 0.05, n = 44) as well as MMP-3 levels (r = 0.58, p = 0.0001, n = 45). Similarly, active MMP-2 levels were significantly associated with MMP-2 precursor levels (r = 0.64, p = 0.0001, n = 72), MMP-3 levels (r = 0.63, p = 0.0001, n = 49), active MMP-9 levels (r = 0.49, p = 0.0001, n = 72) and MMP-9 precursor levels (r = 0.53, p = 0.0001, n = 72).
We conclude that in contrast to our findings with uPA, MMP-1, 2, 3 and 9 levels were generally higher in both BCCs and SCCs relative to malignant melanomas. The low metastatic potential of both BCCs and SCCs is therefore unlikely to be due to a deficiency of these MMPs. Matrix metalloproteinases (MMPs) are Zn-dependent endopeptidases which catalyse degradation of diverse substrates in the extracellular matrix. In vivo, activity of these MMPs is controlled by a group of inhibitors known as TIMPs. In many model systems, metastatic potential is positively correlated with MMP levels and negatively associated with TIMP levels.
The aim of this study was to establish the relationship between levels of TIMP-I and metastatic potential in human breast carcinomas. Results: mRNAs for MMPs-2, 7 and -9 were expressed significantly more frequently in tumour than normal mucosa (p-0.05 X). Of the TIMPs. TIMP-2 but not TIMP-1 was significantly expressed in tumour compared to normal (p=0.05 X'). There was a highly significant increase in the quantity of mRNA for MMPs-2, and -7 in gastric cancers (p<0.0 I Mann-Whitney) and a less marked but significant increase in TIMP-2 mRNA (p<0.05 Mann-Whitney).There was a trcnd to significance in the increased expression of MT-MMP-1 in tumours. Gelatin zymography revealed both forms of Membrane mediated metalloproteinase (MMP) activity is proposed to be an essential requirement for the metastatic development of the cancer cell, since it is this activity which is responsible for matrix remodeling which facilitates the egress of the metastatic cell through basement membrane components into the vasculature. In light ofthis it is proposed that members ofthe MMP family are instrumental in cellular dissemination, due to their type IV collagenase activity.
We report here the expression of several members of different metalloproteinase families in the breast carcinoma cell lines MCF-7 and T47D. Using RT-PCR The stroma is believed to play a regulatory role in epithelial cell proliferation and differentiation during homeostasis and tissue regeneration. Dysregulation of these processes is implicated in the development and progression of neoplastic disease. We have used differential display RT-PCR to identify changes in gene expression induced when normal human urothelial (NHU) cells interact with basement membrane-derived Matrigel matrices.
Total RNA was extracted from NHU cells grown on Matrigel or Primaria tissue culture plastic for 24 or 48 hours. After removal of contaminating DNA, differential display RT-PCR was carried out using 30 primer combinations. The differential display products were analysed on sequencing gels. 27 bands showed a relative increase in intensity and were excised from gels, re-amplified and cloned into pGEM3Z. Up to 6 clones from each band were sequenced and homologies assessed by DNA database comparisons.
Upregulation of gene expression by cells grown on Matrigel was confirmed by Ribonuclease Protection Assays (RPA) for 9 independent sequences, including 4 ESTs and 5 known genes: connexin 26, macrophage migration inhibition factor (MMIF), cystatin B, elafin and antileukoprotease. These genes have recognised roles in cell:matrix and cell:cell interactions, although only connexin 26 expression has previously been studied in bladder cancer. By RPA, three of the mRNAs (connexin 26, MMIF and elafin) were absent from urothelium in situ, suggesting that expression of these genes forms part of the inducible response repertoire of urothelium.
This approach has identified novel and previously non-implicated gene products involved in normal urothelial:matrix interactions which may be significant in the development of invasive and metastatic tumour phenotypes. Furthermore, the identification of cystatin B (a cysteine protease inhibitor) and the serine proteinase inhibitors, elafin and antileukoprotease, raises the possibility that this approach may be useful in identifying novel protease inhibitors. E-cadherin, a cell adhesion molecule, has been widely employed as a marker in a variety of human tumours' including colorectal cancer. P-catenin, a protein believed to regulate enterocyte proliferation and apoptosis, binds with E-cadherin as part of the cadherin-catenin complex which is of importance in cell adhesion. The product of the tumour suppressor gene, APC, competes with E-cadherin for binding of Icatenin 2 The expression of both E-cadherin and P-catenin has been shown to be reduced in colorectal cancer.
A mutant mouse lineage which exhibits inherited predisposition to multiple intestinal neoplasia (Min) has long been used as a model to study familial adenomatous polyposis (FAP). Both the Min/+ mouse and patients predisposed to FAP carry a germline mutation in the Apc gene3.
The aim of this study was to utilise the Min mouse model to compare the level of expression of both E-cadherin and P-catenin from early through to late stages of malignancy. Min/+ mice were terminated at either 4 weeks, 8 weeks or 12 weeks of age and the large intestine removed. Tumour and surrounding tissue were excised from five areas along the length of the intestine, formalin fixed and paraffin embedded. The intestinal mucosal samples were analysed by immunohistochemistry to examine the expression of both E-cadherin and 0-catenin. Control samples were obtained from representative areas of the large intestine of both Min/-and C57BI mice terminated at the same age.
Tissue sections were examined for differences in the expression of E-cadherin and 0-catenin between the normal intestinal mucosa and that of the tumour. Essentially the level of expression of both proteins was found to be correlated with the degree of malignancy when compared to the normal. Membranous versus cytoplasmic staining of the proteins was found to vary between the samples,with a loss of membranous staining indicating a reduction in cell adhesion. This study has enabled some of the early changes which may occur in colorectal cancer to be identified. Normal and malignant breast epithelia express and often secrete mucins, and their cellular upregulation has been reported in breast tumours. Elevated serum levels post-surgery may reflect the subclinical development of metastatic disease.
The C595 anti-MUC I antibody would not titrate on T47D breast carcinoma cell lines (median channels 213 to >609, control= 2.1) so the MCF7 breast carcinoma cell line was used having a lower level of expression of MUC I (Med. Ch 10, contol 2.0). MUC I expression was upregulated by cytokines (30% increases with G-CSF, GM-CSF, and IL-I; and 120% increase with IFNy).In contrast, the intercellular adhesion molecule (ICAM-1, CD54) was upregulated by both IL-I (150%) and IFNy (300%).
Association and dissociation studies were undertaken with FITC conjugated C595 (F:P ratio 6:1) at room temperature over 10-20 minutes. Cells were pre-labelled with unconjugated Ab, then exposed to excess FITC conjugate, or vice verca, and changes in fluorescence detected over time (dissociation); or fluorescence measured after adding FITC C595 alone (association).
The association constant of 5ul (=5ug) Tissue-specific genes provide information regarding the structure and/or function of that tissue and may be used as molecular markers of a particular cellular phenotype. The ability of the associated promoter / enhancer elements of such genes to direct transgene expression in a tissue specific manner has been exploited to produce specific cancer models and direct therapeutic gene expression. Our aim was to identify novel urothelial specific genes with expression retained following neoplastic transformation.
Differential display RT-PCR was performed with 30 primer combinations on autologous DNAse treated mRNA from bovine lung, oesophagus, bladder, liver and spleen. 21 bands derived from cDNA products suggesting urothelial specific mRNA expression were isolated and T-A cloned into pGEM vectors. Database homology was assessed for the 33 discrete differential display products identified by sequencing.
Sequences identified included uroplakins la and 11, two of the three genes previously known to have urothelial specific expression. 19 of the sequences had no homology with sequences on the GenBank database.
Ribonuclease protection assays were performed to confirm the tissue specificity of a number of the cloned products. Three of the seven novel sequences tested were confirmed to exhibit urothelial-specific expression.
A bovine urothelial cDNA library was screened using riboprobes generated from the differential display products. Four discrete clones ranging between 700 and 1650 bp were isolated for one of these sequences. More than 1000 bases of additional coding region sequence was obtained by PCR of the cDNA library using vector and sequence specific primers. RT-PCR of both coding region and 3' UTR confirmed the urothelial specificity of the gene.
Analysis of the assembled sequence identified significant homology within the coding region to previously described urea transporters, a family of proteins responsible for the active transport of urea across plasma membranes. This suggests the identification of a novel gene which acts as a urea transporter within the urothelium of the urinary tract. The present investigation was initiated to produce derivatives of anti-MUCI mucin antibodies which would have the potential for use in tumour targeting. Here we describe the production of a recombinant diabody fragment incorporating the variable region of the anti-MUCl mucin monoclonal antibody C595, using a bacterial expression system used to produce C595 scFv'. The shortened linker method was employed to alter the C595 scFv linker sequence between VH and VL from (Gly4Ser)3 to Gly6Ser. This was achieved using a four primer PCR system. The Gly6Ser linker sequence in the expressed protein no longer allows intramolecular pairing of the VH and VL domains of the scFv as highlighted by modelling studies. These domains then pair with complementary domains on neighbouring molecules, to form a bivalent monospecific scFv dimer (diabody).
Detailed analyses of the binding characteristics of the C595 diabody show these to be similar to those of the parental monoclonal.
Its ability to bind to MUC1 expressing tumours and cell lines identifies it as a potential targeting reagent so that development of diagnostic and therapeutic applications are appropriate. 'Denton et al (1997) Phenylacetate (PA) is a nontoxic cell differentiation inducer, which has been shown to reduce the invasiveness of prostate cancer cells in in vitro assays (Samid D, et al. J Clin Invest. 91: 2288 -2295 , 1992 and is currently in phase I trials for solid tumors (Thibault A, et al. Cancer Res 54: 1690 -1694 , 1994 Anti-VEGF antibodies were produced using filamentous phage technology as previously described3. Phage expressing single chain Fv (scFv) were subjected to 4 rounds of panning on VEGF coated tubes to isolate those reactive with VEGF. Five of these were selected for further analysis on the basis of their DNA sequence diversity, intensity of signal in VEGF binding ELISA and by immunohistochemistry to assess reactivity with blood vessel endothelium.
The selected scFv were subcloned into an expression plasmid incorporating a His6 tag. scFv proteins were purified from culture supernatants by metal chelate chromatography with yields ranging from 6 to 60mg/L. Purified scFV were biotinylated and used in immunohistochemical studies to examine binding to human placenta, normal human colon, human colorectal carcinoma and human colorectal xenografts (LS174T; SW1 16; SW1 22).
Three of the five scFv clones tested did not show significant reactivity with any of the tissue sections tested. A further clone showed weak staining for placental trophoblast and blood vessel endothelium and weak binding to stromal cells in the other tissue sections but did not show any specificity for blood vessels in human tumours or human tumour xenografts. scFv clone L4.6 however reacted with both blood vessels endothelium and syncitial cells in term placenta and was positive for both blood vessel endothelium and stromal cells in colorectal carcinoma and human xenograft tissue. Reactivity with the epithelium of the human carcinoma and with the xenograft tumour cells was heterogeneous. Blood vessels in normal colon were also positive. scFv clone L4.6 targets blood vessels in human tumours and human tumour xenogratts and therefore merits further study as a vehicle for antibody-directed delivery of agents to tumour tissues in both animal models and as a model for potential use in patients. IRL 1620 was administered to anaesthetised rats by bolus i.v. injection at a dose of 1, 3 or5nmol kg-'. Blood flow in the tumour and normal tissues was measured 20 min later, by the uptake of 25I iodoantipyrine (125I-IAP). Blood flow in the tumour decreased dose dependently to 0.4 of the control blood flow, in contrast to the majority of tissues in which blood flow was unchanged. The exceptions to this were the brain and heart in which blood flow increased by a factor of 1.2-1.5 at all doses, and the small intestine in which blood flow was also reduced to 0.5 of the control value, at all doses tested.
Changes in the spatial distribution of tumour blood flow were examined in a group of rats treated with 3nmol kg-' IRL 1620 (bolus i.v.), compared to that in saline treated animals. Blood flow was measured by the uptake of "C-IAP and spatial distribution of blood flow measured by autoradiography. Blood flow in the tumour periphery was higher than that in the central region of the tumour (0.76±0.10 versus 0.49±0.09 ml g' -min"'). Research, 57, 1829) . In the present study, the vascular effects of CA4-P were investigated in more detail in rats bearing the P22 rat carcinosarcoma. Blood flow to s.c. tumours and normal tissues was measured using the uptakeof '25-labelled iodo-antipyrine ('25-IAP). Rats bearing the P22 tumour growing in transparent window chambers implanted into the dorsal skin were used to measure tumour vascular parameters at the single vessel level.
Tumour blood flow was reduced to 12% and 0.9% of control levels at Ih and 6h respectively following 100 mg -kg' CA4-P i.p.. Significant but smaller reductions in blood flow were also observed in normal skin, skeletal muscle and spleen at 1 h. No significant reductions were found for brain, heart, kidney and small intestine at I h. At 6h, blood flow to the brain had decreased to 80% of control levels with no significant change in heart, kidney and small intestine.
The gross tumour vascular changes induced by 100 mg* kg-' CA4-P i. Matrix metalloproteinase (MYI) inhibitors are under investigation as potential therapeutic modalities for treatment of invasive growth and metastasis of many tumour types. The aim of these studies was to evaluate the effect of the broad spectrum MM? inhibitor, marimastat, on the growth of a CEA-secreting human gastric xenograft, MGLVAl, allowing any relationship between therapeutic effect and serum CEA levels to be determined.
MGLVA1 was shown by RT-PCR to express mRNA for MT-MMPI, MMP-7 and MMP-9. Zymography revealed the presence of MMP-9 activity as well as the inactive and active forms of MMP-2. For the therapy experiments MGLVA1 tissue was implanted subcutaneously into both male and female nude mice. Dosing with marimastat (15mg/mi is osmotic mini-pump, equivalent to approximately 7.2mg/kg/day) began on day 1 and continued throughout the course of the experiment. Control mice were implanted with vehicle-containing pumps. Cross sectional tumour measurements were taken twice weekly using callipers. and animals were terminated when tumour cross sectional area reached 300mm2.
All experimentation was performed according to UKCCCR guidelines. Marimastat was shown to significantly inhibit tumour size in both male and female mice when compared with the respective vehicle controls (p=0.008 1. p=0.0306. respectively on day 17, Mann Whitney U non-parametric test). Marimastat also exerted a significant effect on survival (p=0.001, Log Rank test) with median survival increasing from 18 days to 30 days.
A further experiment was designed to assess the effect of marimastat on circulating CEA levels. Marimastat or vehicle was delivered as above, and the ability of marimastat to significantly inhibit tumour growth was confirmed. The plasminogen activation system plays an important role in the metastatic spread of tumour cells and includes various proteases such as tissue-type (tPA) and urokinase-type (uPA) plasminogen activators, These enzymes convert plasminogen to plasmin, a broad specificity enzyme which degrades a range of extracellular matrix molecules thus contributing to the invasive potential of the tumour cell. In this study, we have examined the effect of retinoic acid (RA) and pentoxifylline (PX) on uPA and tPA secretion by the Hs294T and C8161 melanoma cell lines using a specific ELISA detection system.
We have previously shown that the Hs294T cells are poorly metastatic in vivo in comparison to the aggressive C8 161 cell line. uPA is known to bind to a uPA receptor (uPAR) on the cell surface and we were able to detect membrane-associated uPA in both cell lines using confocal microscopy. The highly aggressive C8161 cell line secreted a 277-fold higher level of uPA (1300fg/cell) than the Hs294T cells (4.7fg/cell). We examined the effect of exposure of the cells to retinoic acid (10-10 -10-5 M) for 4 days on both uPA and tPA production. At 10-7M RA, uPA levels were increased 1.2-fold in the Hs294T cells and by 2.2-fold in the C8161 cells. PX treatment (250[tg/ml) also increased uPA production 2.7-fold in the Hs294T cells and by 1.7-fold in the C8161 cells. The Hs294T cells which secreted lower levels of uPA were found to produce higher levels of tPA (25.6fg/cell) compared to the C8161 cells (4.3fg/cell). RA stimulated a 2.5-fold increase in tPA at 10-7M and a 3.7-fold increase at 10-5M in the Hs294T cells.
These results demonstrate that both PX and RA increase uPA production, while only PX increases tPA expression in these cell lines. Polyunsaturated fatty acids (PuFA) can inhibit the growth of carcinoma cells in vitro. Normal human urothelial (NHU) cells, which prolliferate rapidly in vitro, are also growth inhibited by 72h culture in the presence of n-3 and n-6 PuFA, whereas monounsaturated and saturated fatty acids had no effect (Southgate et al. Br. J. Cancer 1997; 74: 728) .
Although PuFA can induce an apparently irreversible growth arrest at higher concentrations, it is not clear whether there is a cytotoxic effect distinct from the cytostatic mechanism operative at lower PuFA concentrations. p53 is involved cell cycle regulation and cell death, although whether PuFA operate through p53 is unknown.
NHU cell lines were transfected with the HPV16 E6 gene to disable p53 function. The effects of short (72h) and long-term exposure to BSAcomplexed n-3 (eicosapentaenoic) and n-6 (linoleic and y-linolenic) PuFA on NHU and homologous NHU-p53NULL cells was investigated. Cells were cultured in various PuFA concentrations to identify the maximal tolerated dose allowing survival for the normal lifespan of the culture.
NHU cells cultured continuously with PuFA showed a reduced growth rate relative to BSA-only controls. The maximal concentration of ylinolenic acid tolerated in prolonged culture was 10pM, a non-cytostatic dose in short-term culture. The maximal sustainable dose for linoleic acid was 4OpM, which decreased thymidine incorporation by some 60-70% in shortterm culture. Cells in eicosapentaenoic acid could sustain a dose of 20jM, which inhibited thymidine incorporation by 50% in short-term cultures. The p53NULL cells showed the same response patterns to PuFA as untransfected cells.
Thus, the cytostatic and cytotoxic effects of PuFA on normal human urothelial cells are distinct phenomena, probably acting through discrete We are currently investigating whether the combined use of DMXAA with antibody-directed enzyme prodrug therapy (ADEPT) [2] will also enhance therapeutic potential. In ADEPT therapy a F(ab')2 A5B7-enzyme (carboxypeptidase G2) conjugate is administered at 25 enzyme units/mouse and allowed to localise to the tumour and clear from normal tissues. The second phase, the non-toxic prodrug However, long-term prognosis is still poor, presumably due to malignant cells escaping retinoid control. Understanding the mechanisms by which retinoids and their receptors interact with cellular the regulatory pathway and prevent malignant progression, is an important aspect of the development of novel treatment and preventive strategies.
We have developed a unique panel of human primary oral cell cultures, representative of the various stages of tumour progression ie. normal healthy oral tissue, a range of early dysplasias, late stage tumours and metastasis. Using these cultures has allowed us to look at differences in expression of the retinoid receptors and cellular binding proteins, responsible for mediating the biological effects of the retinoids, at different stages of progression. Northern analysis showed that there were no consistent changes during oral cancer progression of the levels of the nuclear receptors, retinoic acid receptors a and y (RARs), and retinoid X receptor-n (RXR) and cellular binding proteins (CRBP and CRABP-II) expressed in these cells. Previous work has shown that loss of RAR-0 is one of the most consistent changes occurring during oral cancer progression which is confirmed in this system. In addition we have demonstrated that RAR-0 loss occurs early in progression and that this loss is associated with a change in cell phenotype from senscence to immortality during the dysplasia stage (McGregor et al., 1998, Cancer Research 57, p3886) . In addition this change in phenotype may occur independently of the loss of CDKN2A/pl6 expression. This work is funded by the A.l. C.R (uk) and the CRC. mechanisms, neither of which involves p53. The two events operate at differing concentrations, which imply that different compositions and amounts in the diet may be significant. Cancer cachexia is characterized by progression of wasting in adipose tissue and muscle following tumour growth. Muscle is more important to the quality of life of cancer patients, but the cause of muscle wasting is not well understood. We surmised that some plasma factor has an inhibitory effect on myoblast proliferation, and that the ability of muscle cells to regenerate decreases following tumour growth. We then hypothesized that the plasma factor could be removed by plasma perfusion, and that myoblasts would be able to proliferate from the satellite cells of the muscles of rabbits whose plasma was perfused. We therefore measured the proliferation of myoblasts from tumour-bearing rabbits in primary culture as a means of confirming our hypothesis. Rabbits implanted with VX2 carcinoma were treated by cyclic plasma perfusion, and the results was less weight loss and longer survival than in untreated rabbits. The urinary 3-methylhistidine/creatinine ratio was less elevated in rabbits treated by cyclic plasma perfusion than in the untreated rabbits. The DNA synthesis rate of myoblasts from rabbits treated by cyclic plasma perfusion was much better maintained than in myoblasts from untreated rabbits. Plasma fractions obtained from a rabbit with VX2 carcinoma and eluted from a phenyl-Sepharose column at NaCI concentrations under about 1.0 M decreased the myoblast proliferation and DNA synthesis. These results suggested that some humoral factor in plasma of rabbits with VX2 carcinoma inhibits proliferation of myoblasts and the deterioration of muscle may be improved by plasma perfusion. Patients with advanced malignant disease display appetite loss and weight loss known as cancer cachexia. In this study, we used cachectic rabbits transplanted with VX2 carcinoma to determine the abnormality of body fat store and lipid metabolism in comparison with starved rabbits where a simple reduction in food intake causes loss of body fat. In addition, the effect of plsama fractions from rabbits with VX2 carcinoma or from starved rabbits were examined. After chromatography of plasma from rabbits with VX2 carcinoma on a phenyl-Sepharose column, a portion of a fraction was added to the culture medium of murine 3T3-LI adipocytes, and the amount of glycerol released into the medium was measured as an index of lipolysis.
To other cultures, a plasma fraction obtained in the same way from rabbits without tumours and fed as usual (controls), or from such rabbits with feed withheld, was added Glycerol release into medium from 3T3-Ll cells treated with the plasma fraction of cachectic rabbits or with the same fraction from starved and healthy control rabbits were 0.370, 0.265 and 0.288 The mechanisms by which fatty acids (FA) may suppress or enhance tumour development and/or progression are unclear. The antiproliferative or cytotoxic effects of polyunsaturated (PuFA) on carcinoma derived cell lines may represent a general response of rapidly proliferating epithelial cells, rather than a feature of the transformed epithelial phenotype. This would be in agreement with findings that PuFA were growth inhibitory to normal human urothelial (NHU) cells, which have a high proliferative index in monolayer cultures (Southgate et al, Br J Cancer 1996; 74:728.) .
The aim of this study was to establish the effect of PuFA on urothelial cells in a homeostatic tissue environment at equilibrium.
Organ cultures were established from surgical specimens of normal urothelial tissues and maintained at an air-liquid interface. Media were supplemented with BSA-complexed FA (stearic, oleic, linoleic, y-linolenic, alinolenic, icosapentaenoic and docosahexaenoic acids). In all cultures, initial regeneration of the urothelium was followed by maintenance of a long-term homeostasis, with low cytoproliferation, preservation of a normal stratified transitional epithelial morphology and expression of characteristic differentiation-associated antigens.
Whether added at initiation of culture or following attainment of equilibrium, PuFA had no apparent effect on urothelial cell proliferation, as determined by histological criteria or immunolabelling for Ki67/MIB-1. Even concentrations of PuFA which were irreversibly cytostatic on monolayer cultures of NHU, did not apparently affect attainment or maintenance of homeostatic equilibrium. PuFA also had little discernible effect on the production of basement membrane components (laminin, collagen IV) or on the expression patterns of E-cadherin or cytokeratin isotypes (CK7, CK8, CK13, CK17, CK18, CK19) characteristic of the normal tissue in situ and of control organ cultures.
These findings show that PuFA have little effect on quiescent urothelial cells in a homeostatic tissue environment, compared with the dramatic effects on isolated, rapidly-dividing cells in monoculture. This supports the hypothesis that anti-proliferative effects of PuFA are related to baseline proliferation rate. RC-160 (octastatin/vapreotide) is a potent octapeptide analogue of somatostatin with growth inhibitory activity in experimental tumours in vitro and in vivo including breast cancer. The efficacy of high dose RC-160 was studied in 14 women, age range 37 -80 years (median 58.5 years) and performance status 0 -2, with pre-treated metastatic breast cancer. The RC-160 was administered by continuous s.c. infusion. The starting dose was 3 mg/day in week 1 and was increased to 4.5 mg/day for weeks 2 to 4 and subsequently to 6 mg/day until end of treatment. A significant reduction in IGF-I levels occurred by day 7 (p<0.0001) and was maintained throughout the treatment. The lowest dose of RC-160 produced the maximal IGF-I response. Although there was no reduction in prolactin levels in patients whose baseline levels were normal, elevated prolactin levels found in 3 patients fell to within the normal range 7 days after commencing RC-160 treatment. RC-160 was well tolerated with no dose reductions being required.
No grade 3 or 4 toxicities were seen. The most common side-effects were mild fatigue and diarrhoea the latter being associated with steatorrhoea in 5 cases. Abscess formation developed at the infusion site in 8 patients and erythema and discomfort was seen in a further 3 patients. A small but significant rise in fasting blood glucose levels was also recorded (p=0.0012), the highest level on treatment being 7.6 mmol/L. No HVman intestinal foetal tissue at 12-20 weeks gestation was retrieved and washed. The epithelial tissue was then desegregated mechanically and enzymatically by collagenase and dispase, and then differentially centrifuged to obtain a homogeneous population of crypt progenitor epithelium. This preparation was then grafted subcutaneously (20ul/graft) into SCID (severe combined Immunodeficient) mice and the graft retrieved at intervals of 7, 14, 21, 35, and 50 days after grafting to study the morphological features and differentiation processes.
21/26 grafts were successfully taken. Distinct stages of regeneration were seen; at early stages of regeneration (7 days) a 'blastema' of undifferentiated cells were seen, this then gave way to crypt formation at 21 days, with crypt fission and early morphological features by 35 days, by 50 days cytodifferentiation and morphological maturation was observed. We present here a novel method of human intestinal epithelial regeneration to aid in the study of molecular regulation at all stages of intestinal epithelial regeneration. Bombesin-like peptides have been shown to be mitogens for human breast cancer cells but the possibility of an autocrine role for gastrin-releasing peptide (GRP) remains unclear. We have investigated the production and inactivation of GRP-like peptides and their growth effects in human breast cancer cell lines. Radioimmunoassay detected GRP-like immunoreactivity (GRP-LI) in T47D breast cancer cells but not in their conditioned medium, indicating rapid degradation. No GRP-LI was found in the ZR-75-I or MDA-MB-436 cells or their conditioned medium. HPLC analysis of the GRP-LI in the T47D cells revealed a major immunoreactive peak whch co-eluted with GRP18-27 and a minor more hydrophilic peak. In vitro stimulation of T47D cell growth by bombesin was enhanced to 154% of control levels by the addition of the selective EC 3.4.24.1 1 inhibitor phosphoramidon (I ngmil 1). Fluorogenic analysis using whole cells confirmed low levels of this enzyme on the T47D cells. This phosphoramidon-sensitive activity was approximately 100-fold less than that measured in the SCLC cell line NCI H345 where EC 3.4.24.1 1-mediated regulation of GRP levels has been shown in the past. These results suggest that a GRP-LI autocrine loop may exist in a subset of breast cancer cell lines. These peptides are rapidly degraded and inactivated extracellularly by a enzyme with an EC 3.4.24.11 profile. This enzyme, previously unreported in human breast cancer cells, significantly modulates both T47D basal growth and its response to BN-induced growth. The surgical manipulation of bowel to form a substitute urinary bladder is currently used following radical cystectomy for transitional cell carcinoma. However, it is associated with a number of problems due to the absorptive/secretory nature of intestinal epithelium compared to the barrier function of urothelium. We are developing "composite enterocystoplasty" in which de-epithelialised bowel segments will be relined with urothelial cells generated in vitro. We have shown that adequate numbers of normal human urothelial cells can be generated rapidly in vitro (Hutton et aI, J Urol 1993; 150: 721) . Cells expanded in vitro will reform a histologically normal urothelium when seeded onto de-epithelialised bladder stroma in organ culture (Scriven et al, J Urol 1997; 158: 1147) . Prior to the development of a surgical model in the pig, it is essential to determine if cultured porcine urothelial cells would form a urothelium, or transdifferentiate into enterocytes following combination with de-epithelialised stroma from bowel or stomach.
Porcine stomach was de-epithelialised by dissection, leaving the submucosa. Normal porcine urothelial cells propagated in vitro to passage 2 were seeded onto the de-epithelialised stomach and maintained for 2 and 4 weeks in organ culture. These cells formed a histologically-normal stratified urothelium by 4 weeks. Collagen IV and laminin were expressed along a clearly defined basement membrane at the epithelial:stromal junction. Cytokeratin 13, which is expressed by urothelium but not gastric epithelium in situ, was positive throughout the neo-urothelium. A urothelial-specific differentiation marker, AUM, was expressed along the apical edge of the superficial cells. Identical results were obtained on allogeneic and autologous tissue recombinations.
Thus, urothelial cells can attach, lay down a basement membrane and form a stratified urothelium with expression of appropriate urothelial differentiation antigens when seeded onto stomach sub-mucosa in organ culture. No evidence was found for tissue-specific or instructive stromal signalling. These data support the concept of "composite enterocystoplasty". Overexpression of wild-type ErbB2 transforms cells in vitro and is linked to tumor progression in vivo, but the mechanism by which this orphan receptor exerts its oncogenic effect remains unclear. Here we use isoform-specific receptor antibodies and electron microscopy to show that a tyrosine-phosphorylated ErbB2 subset (PY1222-B2) immunolocalizes to the Golgi distribution following ligand-dependent heterodimerization and transphosphorylation by heterologous growth factor receptors. This localization contrasts with that of activated epidermal growth factor receptors (EGFR*) and a distinct tyrosinephosphorylated ErbB2 subset (PY1248-B2), both of which exhibit a diffuse distribution of punctate cytoplasmic immunofluorescence.
Golgi immunostaining of PY1222-B2 is also induced by cell treatment with the tyrosine phosphatase inhibitor sodium orthovanadate, indicating that tyrosine phosphorylation suffices for ErbB2 localization to this site. Confocal microscopy shows that pre-treatment with the protein transport blocker brefeldin A (BFA) causes dissolution of Golgi immunofluorescence and retention of PY1222-B2 on the plasma membrane, consistent with previously reported effects of BFA on receptor internalization. Immunoblotting studies reveal that BFA priming also diminishes the EGF-inducible PY1222-B2 signal, and that this is in turn associated with shortened EGFR* signalling and EGFR expression. These findings suggest that PY1222-B2 is endocytically targeted to the trans-Golgi network -perhaps reflecting the lack of a lysosomal targeting motif-and raise the possibility that unliganded ErbB2 may promote tumor growth by 'hijacking' liganded heterooligomers to a receptor recycling pathway. MurphyBrooks, 1994; Chow et al., 1994) . EGFR overexpression is associated with poor prognosis (Mellon et al., 1995) and is noted most often in patients with invasive tumours. EGF binding to the urothelial receptor is inhibited at acidic pH (Hagler et al., 1980) . Urinary EGF levels may therefore be higher when pH is less than seven. This study aims to determine whether there is an association between reduced urinary EGF levels, increased urinary pH and EGFR overexpression in tumour tissue from bladder cancer patients. First morning urine samples were collected from 15 bladder cancer patients just prior to tumour resection. The pH was recorded and urinary EGF levels determined using a sandwich ELISA technique (R&D). Formalin fixed, paraffin embedded tissue from the resected tumours was stained by the avidin-biotin complex using the Ab4 EGFR antibody (Oncogene Science). EGFR positive patients (mean 14.2 ng EGF/mg creatinine) had significantly (p=0.0465) lower levels of urinary EGF than EGFR negative patients (mean 20.4 ng EGF/mg creatinine). The mean urinary pH for EGFR positive and negative patients was 6.0 and consequently pH was not significantly associated with EGF or EGFR status.
These results suggest that EGFR overexpression but not urinary pH may account for the reduction in urinary EGF levels in bladder cancer patients. TGFr, is one member of a family of regulatory proteins having variable effects depending upon the cell type, stage of differentiation and ambient growth conditions. It is generally growth inhibitory on epithelial cells, acting via three surface receptors (Type I, II and [H) to regulate GI to S-phase progression via cyclin dependent kinase inhibitors (CDKIs) p 15, p2 1 and p27. In colon tumour progression, TGFr, responses are lost.
Itz-vitro proliferation studies were undertaken using flow cytometry to measure cell cycle, BrDu incorporation. growth factor receptor, and CDKI expression in colon cancer cell lines.
Under serum-free conditions, SW742 cells were unresponsive to Interferon a is used in the treatment of malignant melanoma, with a response rate in advanced disease of 16%. Recently, the ECOG 1684 study has demonstrated a long term survival benefit in an adjuvant setting for patients with resected high risk primary disease treated with high dose interferon a2b. However this benefit is limited to only 1% of patients. These clinical observations suggest heterogeneity in the response of melanoma cells to interferon. Similar variation in response has also been demonstrated in melanoma cell lines in-vitro. An important pathway for signal transduction by interferon, is via the Janus Kinases (Jaks) and Signal Transducers and Activators of Transcription (STATs), although interferon is also known to activate other signalling pathways. Defects in Jak / STAT signalling may be responsible for the interferon resistance of melanoma cells both in-vitro and clinically.
Eight established melanoma cell lines were screened for their sensitivity to the anti-proliferative effects of interferons. Of these, MM418 was found to be the most sensitive with growth inhibition of 80-100%, whereas MeWo was the most resistant cell line, with growth inhibition of 10-40% depending on the class of interferon used. These findings suggest that the resistance of MeWo cells to the antiproliferative effects of interferons is not due to defects in Jak / STAT signalling, but rather due to either defects in downstream elements of the anti-proliferative response, or defects in additional or alternative signalling pathways that are required for this response. To determine the necessity of Jak / STAT signalling in the anti-proliferative response, these cell lines have been transfected with dominant negative Jak I and Jak 2 mutants. Endothelial monocyte-activating polypeptide 2 (EMAP-2) is a novel tumourderived cytokine with proinflammatory properties, modulating endothelial cells, monocytes and granulocytes in vitro, and inducing an acute inflammatory response and tumour regression in vivo (Kao et al., 1994, J. Biol. Chem. 269; 25106) . EMAP-2 is believed to be synthesised as a 34kDa precursor which is converted to the active 22kDa form. Using polyclonal (PoAb) raised against recombinant human EMAP-2 we studied the distribution of EMAP-2 in normal lung, small cell lung cancer, adenocarcinoma, squamous cell carcinoma and carcinoids. In normal lung tissue some smooth muscle cells and macrophages were found to be positive. In tumours, macrophages in some infiltrates were positive and in several cases diffuse staining of the stroma was observed. Tumour cells in all carcinoids were strongly positive, the well-differentiated being the most positive, showing cytoplasmic granular staining. The more poorly differentiated small cell lung cancer cells were negative or showed slight diffuse staining. The well differentiated adenocarcinomas were also positive. Several of the moderately differentiated squamous cell carcinomas showed slight diffuse staining. The strong granular staining of well differentiated carcinoids in immunohistology correlated with the presence of a 34 kDa band, corresponding to proEMAP, detected by Western blotting. Less differentiated carcinoids, with more diffuse staining, showed less proEMAP and more of the processed forms of 20 and 18 kDa) . These data suggest that processing of EMAP may vary between tumours and may be related to tumour differentiation. The aim of these studeis is to improve the clincial "usefullness' of BCG. Our approach involves genetic modification of BCG and other strains of mycobacteria to make them more immunogenic.
Intravesical immunotherapy for CIS with live BCG vaccine is effective.
However, 30% will not respond and there are occaisional serious complications. BCG works by promoting antigen specific and non-specific immune responses. Our previous studies have shown difference in the cytokine profiles between responders and non-responders. Therefore we are engineering cytokine-secretion by M. bovis BCG and M. smnegmatis for cancer therapy.
Using E.coli-mycobacterial "shuttle" plasmids, expression of recombinant genes is driven via the heat-shock-protein promotors hsp60 and hsp7O. The BCG alpha-antigen signal sequence is used to facilitate secretion of recombinant proteins from the mycobacteria. Whilst cytokine expression is driven by the hsp70 promotor. expression of A victoria green-fluorescent-protein (gfp) is driven by hsp60. When excited by UV or laser radiation gfp emits visible green light making it particularly useful for localizing and tracking mycobacteria.
The levels of cytokine expression are highly heterogeneous; EL-7 (10pg/mnl), IL-8 (50ng/ml).. IL-15 (300pg/ml), RANTES (20ng/ml), MCP-1 (50tng/ml), TNFa (100ng/m!). Importantly, these cytokines are in biologically active form. In particular we have studied the effect of r.M. sineginatis-TNF in vitro. Unlike wild-type bacteria these organisms can enhance the display of costimulatory molecules on bladder tumour cells and augment secretion of proinfllunmnatory cytokines such as IL-6, TNF and IL-8. Bacteria recombinant for the gfp igene hlave been studied by immunolluorescent microscopy and tlowcytometry. In particular we have studied their interaction with bladder tumour cell lines.
The unique difficulties of gene expression in mycobacteria, our initial results on the biological activities of inycobacterial-derived cytokines. and the future uses for this system to express tumour antigens will be discussed.
Kcywords: cytokimne, BCGY. inycobactcria. immunotherapy IL-1 5 is a proinflammatory cytokine with a number of actions in common with IL-2 as a result of shared receptor usage. IL-2 is a central component in immunotherapy for renal cancer, but the optimal dose is limited by significant toxicity. IL-15 displays a reduced toxicity to IL-2 in mouse models and therefore may provide an alternative or parallel therapeutic option in renal cancer. In view of the chemoattractant and proliferative actions of IL-15 on PBMC, induction of IL-15 secretion by renal cells could potentially induce local anti-tumour immune responses.
We have demonstrated that IL-15 mRNA is present in a panel of malignant and normal renal cells using RT-PCR, but with no detectable secretion of IL-15 protein as measured by sensitive ELISA and biological assay. Importantly, renal cells express an incomplete set of IL-15 receptor components (IL-15Ra 8/12; IL-2Rp 12/14; IL-2Ry 0/14) and proliferation of renal cells is not affected by exogenous IL-15.
We are currently investigating a range of candidate stimuli for induction of IL-15 secretion from renal cells. A mixed lymphocytetumour culture model using renal cells has been established to investigate the therapeutic potential of IL-15 as an anti-tumour agent. Oncology/ 3National Centre for Medical Genetics, Our Ladys Hospital Crumlin. While allogeneic BMT is a viable therapeutic option for both acute and chronic leukaemia, the problem of disease relapse remains. Possible rescue options in relapsed leukaemia include consolidation chemotherapy or a second BMT but these options are complicated by disease resistance and toxicity effects. A third option is an immunotherapeutic approach involving the infusion of donor lymphocytes from the original donor. This has proved successful option in > 70% of chronic myeloid leukaemia(CML) patients indicating a strong graft versus leukaemia effect. To date we have performed DLI procedures on 6 CML patients who have relapsed from 1-7 years post BMT. A clinical response was seen in all patients following a short period of cytopenia and a clinical remission has persisted for 6 months -3.5 years post DLI. Polymorphic STR-PCR and RT-PCR detection of bcr-abl transcripts(the leukaemia specific transcript seen in CML) was performed at serial timepoints in unseperated peripheral blood or bone marrow and in selected lineages including CD34 and CD2 lineages. Lineage selection was performed using dynabeads attached to the appropriate monoclonal antibody and PCR techniques were modified to allow direct "dynabead PCR". STR-PCR and RT-PCR of bcr-abl has indicated a true"molecular cure" in these patients. In contrast to CML, the response rate to DLI in acute leukemia particularly ALL; is very poor. We report an 11 year old boy with My+ALL who was transplanted in CR1 using a female unrelated donor mismatched at the DRB3 locus. The graft was T-cell depleted ex-vivo with Campath-lM and complement. Engraftment was prompt as judged by interphase fluorescent in situ hybridisation (FISH) and STR-PCR. The patient subsequently relapsed on day 172 post BMT but remission was achieved with Vincristine and prednisolone. DLI was performed at day +294 post BMT and the patient responded within 6 weeks. The patient is currently well with complete donor chimerism and no evidence of disease at 1 year post DLI. Thus DLI can exhibit an antileukaemic effect in both chronic and acute leukameia and is an effective therapeutic option in the majority of CML patients who relapse post allogeneic BMT. It may also be effective in certain cases of acute leukaemia and should be considered if no other therapeutic option is available. Inteileukin-18 (IL-18) is a 22kDa cytokine which is processed b caspase I to a biologically active 18.3kDa form which is a potent inducer of IFNy. As a result IL-18 promotes the development of a cellular, Thl immune respon e, thought to be important in the destruction of bacterially-infected cells and in anti-tumour immunity. Previously we have shown that the mRNA for IL-18 is expressed by bladder. renal and ovarian cancer cell lines but not by neural crestderived tumiours (melanoma, neuroblastoma It is known that expression of the 170 kDa protein P-glycoprotein (P-gp) is responsible for multidrug resistance (MDR), characterised by development of tumour cell resistance to a wide range of cytotoxic drugs. P-gp acts as an ATPdependent transporter, increasing drug efflux and preventing effective therapy. Various studies have demonstrated that the expression of P-gp in a number of cell types is associated with chloride (Cl-) currents which are activated by cell swelling (reviewed by Higgins, 1995) . Tamoxifen is known to block the swell-activated Clconductance (Zhang et al., 1994) and modulate the P-gp transporter in cancer cells (Fisher et al., 1996) , both actions are independent of action via the oestrogen receptor. We have examined the breast cancer cell line ZR-75-1 for the presence of swell-activated Cl-currents using the whole-cell configuration of the patch-clamp technique. Cells were bathed in a NaCl isotonic saline, pH7.4 and were dialysed with pipette solution containing NMDG-CI, ATP (2mM) and tamoxifen (10 microM), pH7.4. Cells were held (Vh) at -60 mV and stepped from -120 to +60 mV in 2OmV increments. Using this protocol cells bathed in the isotonic saline displayed an outward Cl-current of 3.0±1.1 pA/pF at +6OmV. Upon exposure to an 75% hyposomotic solution the cells showed an increase in the CY current to 20.4±10.2pA/pF (n1l 1, P<0.001, paired t-test), which was reversible upon returning to isotonic conditions. The conductance was confirmed to be selective for Cl-after replacement of the bath solution with a low Cl-solution reduced the outward current. In the absence of ATP there was no increase in current after exposure to hypotonic solution (from 2.2±0.4 pA/pF to 3.6±2.2 pA/pF, n=3), indicating ATP dependency. Exposure of swollen cells to 10 microM 4-(OH)-tamoxifen (n=3) and 10 microM tamoxifen (n=l) reduced the outward current by 71-82% and 90% respectively. We have confirmed that ZR-75-1 breast cancer cells have a swell-activated Clconductance, which is ATP dependent and is reduced by tamoxifen and 4-(OH)-tamoxifen. These results resemble previous investigations on other cell types which have been shown to express P-gp, hence the swell-activated Cl-conductance in ZR-75-1 cells may be associated with P-gp and MDR. The use of tumour-antigen transduced dendritic cells to stimulate anti-tumour responses from autologous T lymphocytes was studied. CD83+ dendritic cells were diffentiated from cultured CD34+ cells, obtained from leukapherised blood, using an immunomagnetic cell sorter, and incubated in medium containing a cocktail of cytokines (TNF alpha, SCF, GMCSF). At day one the cultured CD34+ cells were retrovirally transduced with single tumour antigens (MART, MAGE 3, GPIOO and Tyrosinase) or a polyepitope containing three HLA A2 restricted T cell epitopes (one derived from influenza and two from HPV 16) and a mouse restricted epitope. The constructs contained as a marker gene, enhanced green fluorescence protein (eGFP). Transduction was shown not to alter the cell phenotype as determined by FACS analysis (CDIa, CD4, CD Ilc, CD14, CD40, CD54, CD80, CD83, CD86, class II).
Furthermore the stability of transduction over two months was demonstrated by FACS analysis of the eGFP signal. The ability to present transduced tumour antigen was also examined, by the use of T cell clones specific for HLA A2 restricted epitopes of the tumour antigen of interest. T lymphocyte anti-tumour responses were analysed by cytotoxicity assays following repeated stimulation by transduced dendritic cells in an autologous MLR, cultures were restimulated at weekly intervals. Preliminary results show that dendritic were able to present epitopes effectively with recognition of above 20% with a 3:1 target effector ratio using T cell clones. After two stimulations with the polyepitope transduced dendritic cells, T Multiple myeloma (MM) is a malignant disorder where plasma cells accumulate in the bone marrow. The use of FISH to analyse the DNA of MM patients has shown that rearrangements of the immunoglobulin heavy chain (IGH) locus at 14q32 can occur in up to 70% of cases, such a frequency can not be detected using conventional cytogenetics. In MM such rearrangements are localised to switch regions, sequences which are normally associated with isotype switching events at the IGH locus. Cyclin Dl located on chromosome 1 1q 13 is commonly dysregulated as a result of a translocation of this gene into the IGH locus in mantle cell lymphoma. Similar translocations, only into the switch regions, are also seen in MM and the overexpression of cyclin Dl occurs as a result of such a translocation. We have used an RT-PCR assay to look for cyclin DI overexpression in patient material. Following reverse transcription, a competitive PCR is utilised to monitor the expression of cyclin Dl against that of cyclins D2 and D3. We have studied 12 MM patients using the same RT-PCR assay and have found no evidence of cyclin DI overexpression suggesting that in clinial cases of MM cyclin Di overexpression is not a common event. We have also used this assay to demonstrate cyclin Dl overexpression in a novel myeloma cell line, K620. Interestingly cytogenetic analysis of K620 cells has shown that there is no translocation of the II q 13 locus to 1 4q32, but rather to other loci (1q32 and 8q24), suggesting an alternative, novel mechanism for cyclin Dl dysregulation.
Evidence suggests translocations involving switch regions in MM are nearly universal and involve a promiscuous array of partner loci. Genes such as cyclin Dl and FGFR3 have been identified in MM cell lines but clearly only patient material will yield evidence for representative molecular events. We have used Southern blotting to screen patients but this lacked the required sensitivity and so have gone on to devise a strategy where FISH will initially identify translocations into switch regions. A PCR-based method will then allow the identification and isolation of translocation breakpoints occurring within switch region sequences upstream of the g, y and a constant regions of the IGH locus. Firstly synthetic oligonucleotide linker units, called Vectorettes, are ligated to restriction digested genomic DNA. Amplification is then undertaken using primers complementary to sequences close to the various switch regions and the Vectorette linker. Vectorettes are designed containing a central mismatching region so that they are only amplified when attached to the end of a DNA fragment, and only after extension has occurred from the target sequence primer during the first cycle. Using this method of Vectorette-PCR we have isolated the breakpoints from JJN3 and K620 cell lines associated with g switch regions. We are currently applying this strategy to DNA isolated from the bone marrow and blood of MM patients. Interleukin-12 plays a central role in cell-mediated immunity, enhancing proliferation and cytotoxicity of activated T and NK cells and inducing interferongamma production. We have investigated the effect of exogenous IL-12 and retroviral gene transfer of IL-12 on the allogeneic immune response to bladder cancer cell lines.
Recombinant retrovirus encoding the p35 subunit, the p40 subunit and both subunits together were engineered. These were used to transduce EJ and RT112 cells singly or in combination. No IL-12 secretion was detected when the p35 subunit alone was expressed. However when EJ but not RT1 12 were transduced with the p40 subunit alone, functional IL-12 was secreted. Functional IL-12 was produced when both subunits were transduced.
Allogeneic peripheral blood lymphocytes were incubated for 7 days with the parental tumour cell lines in the presence or absence of exogenous IL-12 and cytotoxicity against the parental tumour was assessed in a standard chromium release assay. Addition of exogenous IL-12 to the co-cultures increased the killing activity in the EJ co-cultures against the parental tumour and against K562 cells. This effect was seen in a dose-dependent manner at concentrations of IL-12 ranging from 10-10OOpg/ul. This killing could be abrogated by 100 fold cold K562 inhibition. This effect was not seen with RT112 cells which failed to generate any cytotoxicity.
EJ cells but not RT112 cells engineered to secrete IL-12 increased generation of cytotoxic activity of co-cultured lymphocytes. This activity could also inhibited by cold K562 inhibition.
Lymphocyte subsets following co-culture with IL-12 and IL-12 secreting tumour cells were analysed by FACS. An increase in CD56 and CD69 positive cells was seen in all cultures containing IL-12. There was variation in the extent of this increase in different donors. The receptor tyrosine kinase ECK is overexpressed in most melanoma cell lines; the pathology where this elevation is initially manifested, and its possible role in tumor progression are unknown. To determine this we studied biopsies of benign and malignant melanocytic lesions. Normal melanocytes, benign compound nevi, and dysplastic melanocytes did not contain ECK, whereas it was detected in 20% of biopsies of malignant melanoma in situ (MMIS). Primary and metastatic melanomas did not contain immunoreactive ECK. LERK-1 (the ligand for ECK) is a melanoma growth factor (Easty et al., Cancer Res. 55: 2528 -32, 1995 ; in addition, it is angiogenic and a chemoattractant for endothelial cells. LERK-1 colocalised with ECK in MMIS, but was also found in vertical growth phase (advanced) primary melanomas (43%) and metastatic melanomas (67%). Expression of LERK-1 was induced in melanoma cells by proinflammatory cytokines. These findings are consistent with two possible roles for LERK-1 in melanoma development, it may: (1) promote melanocytic cell growth or survival in early lesions, and (2) induce vascularization in advanced melanomas; both of these effects may be potentiated by an inflammatory stimulus. (1251) antibodies to bind to the antigen present in the section. The distribution of bound antibody is then digitally mapped using a phosphor imager (Molecular Dynamics) after exposure of sections to phosphor storage plates. The amount of antigen present will be proportional to the amount of antibody bound in a given area of the section and can be calculated from a standard line generated from a nitrocellulose CEA dot blot assay. In a preliminary study, paraffin sections of breast (7 cases) and colorectal (5 cases) adenocarcinomas were reacted with 125I labelled A5B7 anti-CEA antibody (69 MBq mg-,). 10ml aliquots of 0.3-5 gg g-l CEA were applied to 0.45mm nitrocellulose (Biorad, U.K.) and the dots incubated with radioantibody. After incubation (1 hr) The enzyme DT-diaphorase (DTD, NAD(P)H: Quinone acceptor oxidorectase EC 1.6.99.2) is involved in the bioreductive activation of a number of quinones and is thought to be a possible target for enzyme directed prodrug therapy. This idea is further strengthened by the fact that high DTD activity has been reported for a number of tumour tp but prtcularly non-small cell lung cancer suggestng that a oprisat patients could be selected for prodrug therapy.
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Although it is clearly important to determine enzyme activity in human malignancies versus normal tissues, such biochemical studies give no indication of cellular localisation of enzyme. In addition to biochemical ays on tissue homogenates this ongoing study therefore also assesses tissue tribution of DTD by the use of imtmunohichemitry. Telomerase is a riboprotein responsible for the maintenance of telomeric regions at the ends of eukaryotic chromosomes. Telomeric regions of chromosome are responsible for stabilisation of chromosome ends and the prevention of apoptosis due to chromosome shortening during cell division. As such telomerase is thought to be important in the immortalisation of cells, tumour formation and the function of stem cells. An example of a proliferating cell system is the seminiferous epithelium, a highly complex arrangement reliant upon stem cells to produce large numbers of highly differentiated spermatozoa.
The standard telomeric repeat amplification protocol assay (TRAP) clearly demonstrates high levels of telomerase activity within stem cell based tissues such as the testis. Because any tissue has to be homogenised, the assay cannot identify which cells within such a heterogenous tissue actually possess this activity. The physical isolation of different cell populations, whilst giving some cell specificity, remains an imperfect technique when faced with the wide variety of cell types present in many tissues such as the testis.
Using the adult mouse seminiferous epithelium as a model, this study applies a novel adaptation of the standard TRAP assay to study telomerase activity in cryosectioned tissue. This method enables RNase and heat sensitive telomerase activity to be identified within individual cells of a tissue. The results demonstrate that the nuclei of mitotic spermatogonia and meiotic spermatocytes express telomerase activity. Surprisingly, the non-dividing, differentiating spermatids were also found to possess similar activity, cleary located in the elonting spermatid heads. The late spermatocytes, early spermatids and mature spermatozoa have negligible telomerase activity.
This adaption of the TRAP assay is therefore a useful addition to the standard methods of determining telomerase activity and will allow us, for the first time, to examine the pattern oftelomerase activity within tumour tissues. This work was supported by War on Cancer.
P144 DOES THE ACIDIC DOMAIN OF THE MDM2
ONCOPROTEIN HAVE A TRANSCRIPTIONAL CONTROL FUNCTION? Catherine Bladen*, John Lunec. Cancer Research unit, Medical School, University of Newcastle Upon Tyne, NE2 4HH.
The transforming properties of the MDM2 oncoprotein were originally attributed to its ability to bind and inactivate the p53 tumour suppressor protein. More recent studies have revealed that MDM2 has additional transforming mechanisms which are independent of the p53 interaction. We have characterised alternatively spliced forms of MDM2 which retain transforming ability in spite of losing p53 binding domain sequences (Sigalas et al 1996, Nature Medicine, 2 (8) 912-17 ) and studies with transgenic mice have shown that MDM2 is tumourigenic even in p53 null mice (Lundgren et al 1997, Genes and Development, 11(6) 714-25 ) . These observations have led us to examine the role of alternative potential functions of MDM2, particularly the possibility of a transcriptional regulatory function, as suggested by the presence of zinc-finger motifs in the C-terminal region, including a RING-finger domain, and a putative acidic transcriptional transactivation domain. Here we describe the specific testing of the acidic domain of MDM2 for the ability to act as a transcriptional activation domain by fusing it to the DNA binding domain of a yeast Gal4 transcription factor and tested this hybrid for transcriptional function in a luciferase reporter gene system where the luciferase gene is driven by a Gal4 promoter. A DNA fragment encoding the acidic domain of MDM2 (amino acids was isolated by PCR and cloning from MDM2 cDNA and then subcloned downstream and in frame with the yeast Gal4 DNA binding domain already present in the PSG424 eukaryotic expression vector. Recombinant clones were identified by PCR screening and confirmed by DNA sequencing. These constructs were then co-transfected into NIH3T3 murine fibroblast cells together with the PGS-LUC plasmid, containing a luciferase reporter gene under the control of a Gal4 promoter, and PoGal encoding P-galactosidase to assess transfection efficiency. Expression of the luciferase gene resulting from transcriptional regulation by the MDM2Ac-Gal4 fusion protein was assessed by measurement of luciferase activity using the Dual Light' (Perkin-Elmer) chemiluminescence system and a luminometer to quantify the light emission. Gal4-vpl6 was used as a positive control and the PSG424 vector as a negative control. All transfections were carried out in triplicate. The luciferase activity generated with the intact Gal4-vpl6 positive control was 1914 +/-100 times the background level seen with the vector only negative control, whereas the levels of activity obtained with the MDM2Ac-Gal4 fusion construct were not significantly different from the background; ratio 1: higher in patients receiving cIFNAIL-2/5-FU (n=37) than other studies (n=77). High responses were also seen in patients with lung only as site of disease. Although these results suggest that no harm has come from a period of preliminary surveillance, the fact that the therapeutic benefits including durable complete remission from therapy are confined almost entirely to the good risk small volume asymptomatic patients makes it difficult to justify a policy of surveillance in such patients.
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Oxidative stress in patients receiving early enteral nutrition following operations for hepatic or pancreatic disease. R Gupta', K Patel', JN Primrose', CD Johnson', P Yaqoob2, P Calder2, ' Dept. Surgery, Southampton General Hospital, Southampton S016 6YD, 2 Institute of Human Nutrition, University of Southampton, Southampton SO 16 7PX.
Background: Oxidative stress and septic complications are an integral part of serious inflammatory conditions including serious sepsis and major blunt trauma.
Aggressive nutritional support in the form of total enteral nutrition (TEN) is known to attenuate this phenomenon possibly by reducing translocation of endotoxin or micro-organisms from the gut lumen into the systemic circulation. There is a dearth of such data in respect of patients recovering from major abdominal operations. Aims : The aim of our study was to investigate the effect of Immunologic reconstitution following myeloablative chemotherapy and PBPC rescue was studied by examining the regeneration of the T cell receptor beta chain (TCRBV) repertoire in peripheral blood of patients. The TCRBV usage was analysed in twenty three patients with solid maligancies, before cyclophosphamide priming and monthly following high dose chemotherapy and PBPC rescue, using directly conjugated monoclonal antibodies to TCRBV 2,3,5S2/5S3, 7.1, 8, 9, 17, 21 and 22. Expansions of particular TCRBV families were found in four patients (TCRBV 3, 17, 21 and 22) ranging from 8 -42% of the CD4+ or CD8+ repertoire, which reappeared within two months and were stable for up to eighteen months following PBPC rescue. The expansions in three patients (TCRBV 3, 21, 22) The aim ofthe study was to identity prognostically significant proteins in a group of 63 tumour samples taken from 59 patients having eneucleations for large choroidal melanomas. Tumour from four patients included areas with different clinical morphology (e.g. amelanotic vs. pigmented). McAb expression and DNA ploidy was measured by flow cytometry and correlated to clinical parameters (sex, age ofthe patient, tumour location (cilliary body vs. choroidal), cell type (spindle vs.mixed or epitheliod), tumour volume (<1500 mm vs. > 1500mm) and the presence of metastatic spread); using one-way-analysis ofvariance.
Cerb-B2 and C-myc expression showed association with cell type suggesting differences in cell cycle control between them. Cerb-B2 was found in greater amounts in spindle cell tumours (n=19) than mixed/epitheliod tumours (n=27). Mean /Rank 28.87/19.72 P-0.023. C-myc was also expressed more by spindle cell tumours. Mean/Rank 21.65/13.31 P-0.017 (n= 10 spindle, 21 mixed/epith. Astrocytic tumours are the most conmmno central nervous system tumour in children and approximately a quarter of these are malignant. Although these childhood turnours closely resemble their adult counterparts both, in location and histological appearance, there is evidence that their pathogenesis is genetically different. Cytogenetic and molecular genetic analyses of paediatric astrocytoma have been unable to detect the genetic changes which are characteristic in the adult tumours. Furthermore, loss of heterozygosity at 17pl3.3 and 22q12 are the only novel non-random aberrations to have been described in the paediatric tumours. We have used comparative genomic hybridisation to identify gain and loss of genetic material across the whole genome in a series of ten paediatric malignant astrocytoma. DNA was extracted from either freshly frozen tumour biopsies (7 cases) or 5p±m paraffin embedded sections (3 cases) prior to differential labelling and hybridisation. We have identified gene amplification at lpll-31, 2q21-24, 7p12, 7q21-32, 8p2l.3-24.1, 12q13-pter and 13ql1.2 and genetic loss at 6p21. 9p21, 17p13 and 22q12. Some of these changes correspond to regions to which some adult astrocytoma oncogenes and tumour suppressor genes are known to map; the regions of amplification can chromosome 7 contain the EGFR and MET genes which have been shown to be independently amplified in adult tumours, the large amplicon on 12 contains the CDK4 and MDM2 genes which map to 12q13; the CDKN2/pl6 gene, which is homozygously deleted in 70% of adult glioblastoma, is located at 9p21; and loss at 10pl3-15 corresponds with the location of one of the putative tumour suppressor genes an chromosome 10. It is possible, therefore, that there are some coumnan genetic steps in the malignant progression of both paediatric and adult astrocytoma. The MDM2 proto-oncogene, which encodes a protein binding the p53 tumour suppressor, has been found amplified, overexpressed and in some cases alternatively spliced in a range of human tumours. Although human MDM2 cDNA sequence has been reported, the genomic sequence and organisation have not been documented. Since MDM2 has demonstrated a complex pattern of expression, including altemative splicing and differing transcriptional start sites, a genomic sequence map becomes essential to deciphering this gene's function. To this end, we amplified genomic DNA using long range PCR techniques with primers based on the known cDNA sequence. Genomic PCR products spanning introns were cloned into the pUAg vector (Ingenius) and sequenced by automated and manual methods.
We have now obtained complete PCR products and boundary sequences for all introns. Our data shows that the MDM2 gene spans approximately 32 kb and is divided into a minimum of 12 exons. Exon sizes range from 71 to greater than 1159 bp. Intron sizes vary from 121 to 7000 bp. All the splice donor and acceptor sites follow the "GT-AG" rule. Comparison with the murine genomic map data indicates sustantial differences in the size of corresponding introns. In addition, exon/intron boundary sequences have disclosed that the variant transcript forms of MDM2 gene reported previously by Sigalas, et al (Nature Medicine 1996 2: 912-917) are generated by alternative splicing mechanisms. The sequence map has also revealed a promoter-like region in the near 3' end of intron 3 and has led to the investigation of this as a second putative p53-dependent promoter. (Gleeson et al., Cancer Research, 1996, 56:259) and in associated Barrett's oesophagus (Gleeson et al., Genes, Chromosomes & Cancer, 1998, 21:49) . This study assessed whether such changes occur in SIM at the gastro-oesophageal junction. Methods:
Patients attending randomly selected open access upper gastrointestinal endoscopy lists were invited to participate in the study. Paired biopsies were taken from the gastric body and from the epithelium immediately distal to the squamocolumnar junction. Samples were assessed for evidence of SIM using H&E and PAS/AB staining of tissue sections. Frozen samples demonstrating SIM were assessed for microsatellite instability. Results: One hundred and one patients were recruited to the study. In six cases, the biopsy samples contained squamous epithelium and the remaining 95 cases (44 males, 51 females; mean age of 47 years, range 20-87 years) were assessed for SIM. Sixty patients had a normal oesophagus on endoscopy, 11 had hiatus hernia alone, 20 had oesophagitis or oesophageal ulcer, 2 had Barrett's oesophagus and 2 were not available. SIM was detected in 20 patients (21%), two of whom had Barrett's oesophagus on endoscopic assessment and one who had intra-mucosal carcinoma not detected at endoscopy. In 8 of these 20 cases, the frozen sections did not show any evidence of SIM and a further two specimens were not available for genetic analysis. Microsatellite instability was detected in the 2 cases with Barrett's oesophagus. None of the remaining 7 patients with SIM, but normal junctional mucosa, had microsatellite instability. Conclusions: The incidence of SIM at the gastro-oesophageal junction in randomly selected patients attending our open access centre is similar to that reported previously. The occurrence of SIM is patchy, as demonstrated by the disparity between the parafm and the frozen sections. Finally, we have found evidence of microsatellite instability in patients with Barrett's oesophagus, but not in those with SIM at the gastro-oesophageal junction. We have previously found that strong p53 immunohistochemistry (IHC) staining intensity correlates with poorer patient survival for cPNETs (Jaros et al, BJC, 68, 801-807, 1993) . Subsequent analysis of a group of 96 cPNET's has shown that there is a strong association between overall staining intensity and the percentage of stained tumour cells (labelling index, or LI) . LI of >20% correlated with poorer survival (p= 0.0165, logrank test). However, dideoxy-DNA sequencing of the p53 gene (exons [4] [5] [6] [7] [8] identified point mutations in only 2/8 cases from the intensely staining group and not in the moderate and negative groups, indicating that p53 point mutations are not frequent in these tumours. The potential of p53 function as a prognostic marker in cPNETs was further explored by IHC staining for downstream protein mediators of p53 functions; p2 l/Waf-1, Bc1-2 and Bax expression was examined using corresponding antibodies, monoclonals Ab-l(Oncogene-Science) and 124 (Dako), and polyclonal 13666E (Pharmingen). p21/Wafl was weakly expressed (<5%LI), whereas bax was strongly (>40%) expressed in 69% of the tumours, with LI distributed in a distinct bimodal pattern. Bc1-2 was expressed in only 38% of the cases (LI >0 to 95%). Survival did not correlate with p2l/Waf-l expression (p=0.7195). Although higher Bax-or Bc1-2 expression showed a trend for association with poorer survival, this did not reach statistical significance (p=0.1574 and 0.1268, respectively). This might indicate some de-regulation in the Bax downstream pathway. In addition, no correlation was found between p53 overexpression and the expression of these proteins. In conclusion, pre-treatment analysis for these downstream mediators of p53 function did not provide additional prognostic information to analysis of p53 status alone, the significance of which was confirmed in these extended studies. Introduction: Deletions of chromosome 9 occur in the majority (>50%) of human bladder cancers. There is now evidence that loss of heterozygosity (LOH) involves at least 3 regions on 9q suggesting that multiple chromosome 9 tumour suppressor genes may contribute to the development of bladder cancer.
Methods: We have used microsatellite based deletion mapping to pinpoint the critical region of LOH at 9q34. Single strand conformation polymorphism (SSCP) analysis was used to screen for mutations in the TSC1 gene followed by direct sequencing of bands with altered mobility. Results :LOH analysis at 17 microsatellite loci in 9q34 in a panel of 102 bladder tumours identified 6 tumours with small deletions involving 9q34 only. The minimum region was between the loci D9S149 and D9S66. This region contains the tuberous sclerosis gene TSC1.
TSC1 is predicted to act as a tumour suppressor gene since deletion of the wild type allele is detected in hamartomas which develop in individuals carrying a germline mutation. TSC1 is therefore a candidate 9q34 bladder tumour suppressor. We have carried out a mutation screen of TSC1 in the 6 tumours with discrete 9q34 deletions and in 31 tumours with LOH of the entire chromosome arm.
Primers flanking TSC1 exons were used to amplify the entire coding sequence in 19 fragments for analysis. Several bands with altered mobility have been identified in bladder tumour DNA. Sequencing of these is in progress. Conclusions: A critical region of LOH has been mapped to 9q34 in bladder cancer. This region contains the recently identified TSC1 gene, a putative tumour suppressor. Preliminary SSCP analyses indicate that some bladder tumours contain somatic alterations to TSC1. The nature of these awaits confirmation by DNA sequencing. Oestrogen has been shown to increase tyrosine phosphorylation of several proteins, including c-erbB2, in human cancer cells under ' conditions of growth stimulation (Migliaccio et al, 1993 , Oncogene, 8, 2183 Matsuda et al, 1993, PNAS, 90, 10803) . However, over-expression of c-erbB2 may also confer oestrogen resistance in oestrogen receptor' (ER) positive cells (Pietras, et al, 1995 , Oncogene, 10, 2435 . The interaction of these pathways has not previously been investigated in ovarian cancer.
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In the present study, we have investigated the relationship between oestrogen-mediated growth stimulation and c-erbB2 activation in four ovarian cancer cell lines. PE01, PE04, SKOV-3 and PE014 cell lines'
(ER concentrations of 96, 112, 66 and 0 fmol/mg respectively) were treated with 17p-oestradiol (E2) (10-1OM) for 5 days. Growth stimulation was observed in both the PE01 and PE04 cell lines but not ' in the SKOV-3 (ER-positive) or PE014 (ER-negative) lines. Expression of c-erbB2 and its tyrosine phosphorylation were measured by Western blot analysis using the CB II (Novo Castra) and PY20 (Santa Cruz N Biotechnology) monoclonal antibodies respectively. Relative c-erbB2 levels for unstimulated PEOl, PE04, SKOV-3 and PE014 cells were 1: 2 8 : 2.5 respectively as measured by densitometry. Upon stimulation with E2, PE01 and PE04 cell lines showed increased tyrosine phosphorylation of c-erbB2 over a 15 min time course, this effect being mediated within 2 min. Expression of c-erbB2 remained unchanged' throughout this time period. In contrast, E2 produced no change in either tyrosine phosphorylation or c-erbB2 levels in SKOV-3 or PE014 cell lines.
In conclusion, ER-positive ovarian cancer cells expressing only lowmoderate levels of c-erbB2 showed increased tyrosine phosphorylation when growth-stimulated with E2. These data indicate that these signalling pathways are interactive in ovarian cancer.
